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Diabetes mellitus inflicts an ever growing burden on patients and on the 
population as a whole, not only due to a growing prevalence of type 2 diabetes 
mellitus (T2DM), but definitely also due a worldwide increase in (childhood) type 1 
diabetes mellitus (TlDM) (see Figure 1).[1-5] 
Figure 1. IDF prevalence estimates for 2007 (panel A) and 2025 (panel B) 









source: Diabetes Atlas 3rd edition, © International Diabetes Federation, 2006 
_j 12 Chapter 1 have T2DM. The estimated prevalence of diagnosed diabetes in the U.S. was 17.5 million persons in 2007 (5.8%).[7] Since the discovery of insulin, many advances have been made in the treatment of the disease. Still, despite all innovations in diagnostics and therapeutics, persistent hyperglycaemia and hypoglycaemic events are associated with increased morbidity and early mortality, and with a reduction in health related quality of life of patients with diabetes mellitus.[1] Costs of diabetes in 2007 were estimated to be $174 billion in the U.S. alone; 1 of every 5 health care dollars was spent for someone with diabetes.[7] Large randomized studies performed in the previous century have highlighted the importance of good glycaemic control in order to prevent or delay complications.[8-12] Even after 10 years, these beneficial effects of improved glucose control persist.[13] However, especially in type 1 diabetes, attempts to reach this good glycaemic control may lead to an increased occurrence of severe hypoglycaemic events.[1] Hypoglycaemia is associated with acute (neuro)glycopenia which may lead to short term cognitive function loss with the occurrence of dangerous situations in everyday life as a possible consequence. Luckily, results from the Epidemiology of Diabetes Interventions and Complications study showed no evidence for an association between severe hypoglycaemia and long term cognitive function loss in patients with TlDM (mean age at the time of analysis was 46 years).[14] In contrast, in another study, researchers did find an association between severe hypoglycaemia and the risk of dementia in a cohort study of older patients with T2DM (mean age 65 years).(15] The challenge of diabetes treatment is to reach good glucose control and to avoid large swings in glucose levels as much as possible by finding an equilibrium between food intake, physical exercise, and insulin requirements. Two key factors for a successful treatment of TlDM are a reliable mode of glucose measurement and an effective mode of insulin administration, with predictive effects on glucose excursions. Ideally, an algorithm with feedback loop to link the two together would make human intervention redundant. Insulin administration The route through which insulin is administered has been subject of studies since the extraction and purification of bovine insulin in the 1920's by Banting and Best (see Figure 2).[16,17] �--- --- - ----- --- - -- -
Figure 2. Publication by Banting and Best 
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Subcutaneous, intravenous, intramuscular, intranasal, intrapulmonary, rectal, 
transcutaneous, intraperitoneal, and oral routes have all been studied. The 
subcutaneous route is currently most widely used in ambulatory patients in daily 
practice. The development of insulin analogues and automated insulin pumps 
allows a wide range of treatment options, including intensified insulin treatment 
with continuous subcutaneous insulin infusion (CSII) or multiple daily injections 
(MDI), all aiming at (near)normoglycaemia.[18] 
Almost one fifth of patients with T2DM treated by general practitioners in the 
Netherlands uses subcutaneous insulin.[19] Virtually all patients with TlDM need 
exogenous insulin. Furthermore, it is estimated that in 2002 there were 4700 
patients using CSII in the Netherlands, and some 140.000 in the U.S.[20,21] 
Still, even when administered subcutaneously, wide variations in absorption pattern 
and duration of action are possible, with both intra- and interindividual variations 
of up to 35%.[22] For example, the onset of subcutaneous insulin action varies 
between 5-15 minutes for the rapid acting insulin analogues and 6-10 hours for the 
long acting insulins with an effective duration between 4-6 hours (rapid acting 
analogues) and 20-24 hours (long acting analogues).[23] 
Insulin, when (unintendedly) administered intramuscular has a pharmacodynamic 
and pharmacokinetic profile more or less comparable to the profile of 
subcutaneously administered insulin. A more rapid action with subsequent risk of 
hypoglycaemia, especially with exercise, has been reported, however.[24,25] 
Intravenous (IV) administration provides a rapid and predictable action of insulin, 




studies in the 1980's showed, that long term use of IV insulin in ambulatory 
patients is accompanied by frequent infections and complications, this route is 
nowadays only used as a temporary or last-resort option.[26,27] Oral and intranasal 
insulin administration are still in the experimental phase.[28] In the fall of 2007, the 
only approved inhaled insulin was taken off the market due to a lack of commercial 
success combined with a possible association of its use with increased risk of lung 
cancer and impairment of pulmonary function.[28,29] 
As an alternative to the mentioned techniques, intraperitoneal (IP) administration 
has proven to be feasible and effective in small (non-) randomized studies in the 
1980's.[30,31] Insulin which is delivered into the peritoneal space is to a large 
extent absorbed directly into the portal system, where it is detectable within 1 
minute of administration, thereby mimicking the physiological route of insulin 
delivery from the pancreas. [32] Peripheral insulin concentrations remains lower in 
comparison with equivalent subcutaneous administration.[32] Furthermore, 
implantation of the pump releases the patient from the burden of external devices 
and daily insulin injections.[33] Unfortunately, complication rates were relatively 
high in the first years following the introduction of the intraperitoneal insulin pump. 
Improvements of the pump itself, the insulin, and the maintenance procedures 
helped to largely overcome these initial problems.[34] Use of continuous 
intraperitoneal insulin infusion (CIPII) is largely restricted to Europe, especially 
France, The Netherlands and Sweden. Nowadays only one of the several earlier 
pump models is still available for use in patients. 
Glucose measurement 
The ability for patients to measure their own glucose levels has also proven to be a 
big step forward in achieving good glycaemic control. Initially, only urine glucose 
testing was widely available, followed by blood glucose testing by means of a 
biochemical reaction between the enzyme glucose oxidase and glucose (1964; 
Ames).[35] Since then, the technology has improved, and current blood glucose 
meters for patient use are small, easy to use and require only a small amount of 
blood and less than a minute of reaction time. The American Diabetes Association 
(ADA) recommends that 100% of measurements performed with home blood 
glucose meters should be within 5% of the reference method value for a meter to 
be considered accurate.[36] None of the currently available meters reaches this 
precision, however.[37,38] The International Organization for Standardization (ISO) 
standard on blood glucose meters requires 95% of blood glucose meter values to 
be within 0.8 mmol/L of the reference values when that value is below 4.2 mmol/L, 
and within 20% of the reference values when the reference value is above 4.2 
mmol/L.[39] A reasonable number of meters perform within the limits set by these 
criteria.[40] 
,.__ _______________________ ---- -------
Introduction 
It is recommended that patients with type 1 diabetes perform self monitoring of 
blood glucose (SMBG) at least 3 times a day.[1,10] However, patients do not always 
comply to this strategy for different reasons, among which fear, and pain 
associated with the blood drawing procedure itself.[41] Furthermore, SMBG is 
found to be associated with a lower quality of life.[42] Still, even with frequent 
SMBG, stable blood glucose control will not always be achieved. To address these 
issues, several types of continuous minimal- or non-invasive blood glucose 
monitors have been developed. Using different technologies, all of these so-called 
glucose sensors aim at providing (near-) continuous information regarding the 
current glucose value without the need for multiple daily invasive actions. Like with 
insulin administration, different sites of glucose measurement have been studied, 
among which intraocular, transdermal, intravenous, and subcutaneous locations. 
Multiple attempts have been made to develop and test really non-invasive devices, 
using measurements of glucose with different techniques. However, despite 
spending many millions in research and development during the last decades, no 
accurate device using these kinds of technology is on the market today.[43-46] 
One example of such a non-invasive technique is spectroscopy using a beam of 
light of the near-infrared wavelength which is directed at the skin, or at the blood 
vessels of the retina, or at the anterior chamber of the eye. A change in glucose 
concentration in those tissues can influence the amount of absorption and 
scattering of the beam of light, which then can be measured and used as a measure 
for glucose concentration.[47] 
Other non-invasive techniques involved reverse iontophoresis or impedance 
spectroscopy. Reverse iontophoresis uses a small electrical current through the 
skin, which forces sodium and chloride ions from beneath the skin towards the 
surface, bringing glucose along to be measured.[47] With impedance spectroscopy, 
changes in skin impedance, caused by differences in sodium and potassium ion 
concentrations induced by plasma glucose concentrations, are measured. 
However, both techniques proved to be inaccurate and patient unfriendly to such 
an extent, that devices based on this technology were either not brought on or 
taken off the market shortly after their introduction.[47-49] 
Assessment of glucose levels using the glucose oxidase reaction is the basis for 
current IV sensors. As with other sensors, that are supposed to work accurately for 
a longer period of time, one of the major problems with IV sensors is membrane 
biofouling; the reaction of the body to a foreign object with the formation of a 
fibrinous clot. Also, vasoconstriction and continuous contact with the vessel wall 
can hamper accurate measurements. Furthermore, intravenous sensor lifetime is 
limited because of mechanical stress with damage of materials used, and by the 
eventual exhaustion of the available glucose oxidase enzyme. This results in 
another major problem with the IV glucose sensor: a surgical procedure to replace 
15 
16 Chapter 1 the sensor is needed every couple of months, with an average longevity of 9 months.[50] Most presently available continuous glucose sensors measure interstitial fluid glucose with glucose oxidase techniques as well. Measurements in the interstitial fluid are indeed related to blood glucose values, but the interstitial levels generally lag behind the capillary or venous levels.[51] This delay is one of the reasons that continuous glucose sensor readings still are not as accurate as capillary blood glucose assessments.[44] The first commercially available glucose sensor did not report glucose values right away; instead, after using the device for some days, the data had to be downloaded on a computer for analysis. Regarding efficacy in terms of HbAlc decrease when using such devices, the evidence generally is lacking.[52] Since then, several manufactures have introduced glucose sensors providing direct glucose readings on the market.[53] This feature, together with the option of setting alarms, make continuous subcutaneous glucose sensors more appealing to patients, especially to those that experience frequent or unexpected hypo- and hyperglycaemic excursions. User acceptance tends to be high.[54] Still, despite high hopes of both patients and diabetes care providers, all the currently available continuous subcutaneous glucose sensors have problems regarding accuracy, the limited sensor life time, and costs to solve. Intermittent SMBG will still be necessary and even mandatory for good diabetes control in the meantime. Aims of the studies In this thesis, different aspects of intensive insulin therapy in type 1 diabetes mellitus and the application of continuous glucose monitoring to assess and alter glucose control have been studied. The first set of studies presents the experience of a single centre use of continuous intraperitoneal insulin infusion (CIPII) up to now. In Chapter 2 results regarding glycaemic control and health related quality of life (HrQoL) in relation to CIPII are presented. The surgical implications of CIPII are presented in Chapter 3. In Chapters 4 and 5 a prospective randomized controlled study is described, comparing the effects of CIPII with regular intensified insulin regimens on glycaemic control, HrQoL, treatment satisfaction and health care costs in type 1 diabetes patients. The use of real time continuous glucose monitoring in patients with type 1 diabetes using CIPII is presented in Chapter 6. The hypothesis was, that more information on glucose metabolism provided through continuous glucose monitoring by use of a real time sensor will lead to a better control with more time spent in the normoglycaemic range. In Chapter 7 the use of a continuous glucose monitor peri-operatively and in an intensive care setting has been studied. 
Introduction 
In Chapter 8 (Chapter 9 in Dutch) a summary of this thesis is given, together with 
some recommendations and future perspectives. 
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Continuous intraperitoneal insulin infusion (CIPII) has been in use for over 20 years. 
High costs and technical problems have prevented a widespread use. In the 
Netherlands, the Isala Klinieken in Zwolle is the centre with the most extensive 
experience with CIPII. Its use is aimed at improving glycaemic control with less 
hypoglycaemic events, and thus improving quality of life in patients with poorly 
controlled diabetes despite intensified insulin treatment. 
Our aim was to assess glycaemic control, health status and treatment satisfaction in 
subjects treated with CIPII within the Isala Klinieken. 
Methods 
Retrospective longitudinal analysis of clinical data in 48 patients initiated on CIPII 
between 1983 and 2005. HbA1c at baseline, after one year, and at present 
assessment or at end of pump use were applicable. Cross-sectional assessment of 
health status, well-being and treatment satisfaction was carried out. 
Results 
33 of 48 patients were treated with CIPII at the moment of assessment. 5 patients 
died whilst on CIPII; 4 by diabetes related causes, none of hypoglycaemia. HbAlc 
decreased significantly from 9.7% to 8.8% after one year, to 8.6% at long term 
follow up; p< 0.01. Less hypoglycaemic events were reported. 
SF-12 scores were 37.4 and 47.2 (range 0-100); WHO-5 score was 52.7 (range 0-
100); Median treatment satisfaction score was 32 (range 0-36). 
Conclusion 
CIPII leads to improved glycaemic control with less self-reported hypoglycaemic 
events in patients with poorly controlled diabetes. Treatment satisfaction is high. 
Mental health status and well-being scores are low however. 
�-------- ---------------------
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Introduction 
Continuous intraperitoneal insulin infusion (CIPII) has been a promising treatment 
for diabetes mellitus for the last 20 years. The use of the peritoneal cavity rather 
than subcutaneous tissue for insulin administration may explain the beneficial 
effect on diabetes control and the lower risk of hypoglycaemia of this treatment 
modality. Insulin delivered through the intraperitoneal (IP) route is better absorbed 
and allows blood glucose values to return to baseline values more rapidly with 
more predictable insulin profiles compared to subcutaneous injections of regular or 
long-acting insulin.[1,2] Furthermore, much of the IP insulin is absorbed by the 
portal system, mimicking the physiological situation and resulting in higher hepatic 
uptake and thus lower peripheral plasma insulin concentrations compared to 
systemic administration.[3] Other possible effects include improvement of the 
impaired glucagon secretion and hepatic glucose production in response to 
hypoglycaemia through alleviation of peripheral hyperinsulinemia.[4] These 
properties may have a favourable impact on hypoglycaemia thus being of 
importance in diminishing risk in subjects experiencing hypoglycaemia 
unawareness. 
Research with IP delivery of insulin in type 1 and type 2 diabetic subjects has shown 
that it is an appropriate therapy that allows subjects to achieve acceptable 
glycaemic control without increasing the inherent risk of severe hypoglycaemia 
observed when intensive insulin treatment is pursued.[5-10] 
Living with diabetes has a major effect on health-related quality of life and well­
being. Not only since it is a chronic disease but also because this disease demands 
performing diabetes related tasks every day.[11] Partly because of this, almost one 
in three people with diabetes suffers from symptoms of depression.[12] This and 
other psychosocial factors are often stronger predictors of medical outcomes such 
as hospitalization and mortality than are measures such as HbA1c or body mass 
index (BMI).[13] 
It is hypothesized that CIPII can have a positive influence on quality of life, not only 
because it can result in better glycaemic control and less hypoglycaemic events, but 
also because it does not require multiple injections as for subcutaneous insulin 
delivery by pen, or because it does not have the inconvenience of an external pump 
as is the case with CSII. Results from clinical trials suggest that CIPII can indeed 
have a positive effect on health related quality of life and well-being.[7-9] 
Such effects provide the arguments to make IP insulin in theory the most effective 
and physiological mode of insulin delivery. However, due to technical problems and 
its high costs it is still not widely used. At this moment the only available 
implantable pump is the model 2007 from Medtronic/Minimed (Northridge, CA, 
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USA), and though CE mark approval enables commercial distribution in Europe, 
there is still no approval by the American Food and Drug Administration. 
In the past, system blockades through insulin aggregates and catheter obstructions 
have been the two major problems resulting in underdelivery of insulin.[10,14-15] 
Due to improvements in the process of preparation of the specific insulin used for 
IP therapy, the occurrence of insulin aggregates is reduced in the recent years.[16] 
Haardt et al compared CIPII with multiple subcutaneous injections and reported 
direct costs of CIPII being 2.6 fold higher.[9] These data are from a decade ago, and 
since then improvements like longer battery life will probably have reduced costs. 
Up till 2001 approximately 1100 pumps have been used world-wide, most of them 
in France.[14] In 2004 406 patients were treated with CIPII.[17] In the Netherlands 
CIPII is only considered as a last resort for patients with so called 'brittle' diabetes 
who are not responding on multiple daily insulin injections (MDI) or subcutaneous 
insulin infusion (CSII), or in patients with subcutaneous insulin resistance.[18] 
The Isala Klinieken in Zwolle is the centre in the Netherlands with the most 
extensive experience with this treatment option. The objective of this report is to 
describe CIPII regarding glycaemic control, health status and patient satisfaction in 
this group of patients. 
Material and Methods 
All patients treated with CIPII and cared for in the Isala Klinieken in Zwolle were 
eligible for the study. Data were collected on glycaemic control, duration of 
diabetes and data on start and cessation of CIPII from hospital records. 
Glycaemic control was assessed using HbA1c prior to implantation, 1 year after 
implantation and at long term fol low up. 
Patients currently on CIPII and treated in our clinic received a questionnaire by mail. 
This survey contained questions regarding number of hospital admissions in the 
previous year, number of self control of blood glucose daily, number of 
hypoglycaemic events in the last 4 weeks and macrovascular complications. Body 
mass index (BMI) was calculated with self reported height and weight for all survey 
respondents and in other cases data from hospital records were used. In addition, 
we asked about perception regarding glycaemic control and hypoglycaemic events 
with CIPII as compared to previous insulin treatment. Finally, using self 
administered questionnaires health status and treatment satisfaction were 
assessed. 
Health status. well-being and treatment satisfaction 
To measure health status and well-being the Short-form 12 item health survey (SF-
12) and the WHO-5 Well-being Index (WHO-5) were used .[19, 20] 
-- -- - - ----------
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The SF-12 is a generic measure of health status and is derived from the Short-form 
36 item health survey (SF-36). Using scoring algorithms two summary scores can be 
derived from the SF-12; the Mental Component Summary (MCS) and the Physical 
Component Summary (PCS).[21] These summary measures are highly correlated 
with the SF-36 summary measures.[19] Gandek et al reported about the high 
degree of equivalence observed in 10 countries (among which The Netherlands) 
and therefore recommend using the standard scoring algorithms. The PCS and 
MCS scores have a range of O to 100 and were designed to have a mean score of 
50 and a standard deviation of 10 in a representative sample of the US 
population.[22] The SF-12 has been found both valid and reliable. Both the SF-36 
and the SF-12 are widely used health status measurement tools. This makes 
comparison of health status of different populations possible. 
The WHO-Five Well-being Index (WHO-5) is derived from a larger rating scale 
developed for a World Health Organisation project on quality of life in primary 
health care.[20] It was designed to measure positive well-being. The WHO-5 is 
recommended by the WHO as a first step in a two stage screening process for 
depression.[20] The WHO-5 consists of 5 items, whereby every answer is given on a 
score between 0 and 5, giving a raw score from O to 25. To allow comparison with 
other scales, the WHO-5 can be transformed to a O to 100 scale. A raw score below 
13, i.e. score below 50 on the O to 100 scale, indicates poor well-being and is 
considered to be an indicator for depression, which should be confirmed using the 
Major (ICD-10) Depression Inventory and patient interviews.[23] High reliability and 
clinical validity of the WHO-5 as a screening instrument of depression and well­
being in people with diabetes was found by Shea et al.[24] 
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was used to measure 
satisfaction with treatment.[25] The DTSQ can be applied for both type 1 and type 
2 diabetes patients. The questionnaire consists of eight items, all scored on a seven 
point scale, ranging from 'very satisfied ' (6) to 'very dissatisfied ' (0). The DTSQ has 
three subscales; Treatment Satisfaction (6 items), Perceived Frequency of 
Hyperglycaemia (1 item) and Perceived Frequency of Hypoglycaemia (1 item).[25] 
The DTSQ has been used in Dutch studies.[26, 27] 
Statistical analysis 
The statistical analyses were carried out using SPSS version 12.0.1. Statistical 
significance was taken at p<0.05. Where appropriate, parametric (Student's t) and 
non-parametric (Mann-Whitney U) tests were used to compare outcome measures. 




48 patients were identified who received an implantable insulin pump for CIPII from 
1983 up till December 2005 in the Isala Klinieken in Zwolle, the Netherlands. At the 
time of our study in December 2005, 33 patients were treated with CIPII. Patient 
characteristics are shown in Table 1. 
Table 1. Patient characteristics 
Characteristic 
n 
Sex (m/f) (n) 













Age at time of implantation (yrs) 36.3 (13.1; 13.8 - 60.6) 36.6 (14.4; 13.8 - 60.6) 
Diabetes duration at time of implantation 17.2 (9.8; 3 - 37) 16.3 (9.1; 3 - 37) 
(yrs) 
HbA1c (%) 9.7 (1.7; 6.1 - 12.6)2 9.9 (1.5; 7.2 - 12.0)2 
Smoking (%) 25 27 
Use of alcohol (%) 49 _4_9 ______ _ 
Values are number of patients, mean (SD; range) or percentage of patients; 1at assessment in 
fourth quarter of 2005; 2missing data due to incomplete dataset; DM= diabetes mellitus 
Reasons for cessation of CIPII are given in Table 2. 33% (n=5) died while on CIPII, in 
4 cases the cause of death was diabetes related, with kidney failure and heart 
failure being the cause of death in 2 cases each. Since cessation of CIPII four 
patients died while on other forms of insulin therapy. 
Table 2. Cessation of CIPII 
Reason for sto ping CIPll 1 n 
Inadequate glycaemic control 4 
Pump failure 3 
Kidney/pancreas transplantation 2 
Recurrent infection of pump 1 
Death of diabetes related complications 
Kidney failure 2 
Heart failure 2 
Death of other cause 1 
1 as recorded in hospital records 
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The response of patients still on CIPII regarding the questionnaire was high with 30 
out of 33 (91 %) questionnaires returned. 
Glycaemic control 
HbA1c levels at all three study points could be retrieved for of 41 out of 48 patients. 
Patients reported less hypoglycaemic events with CIPII. Mean HbA1c before 
implantation was 9.7% (SD 1.7). One year after implantation (median 12.0 months, 
P25 -P75 : 9.5-14.0) HbA1c had decreased significantly to 8.8% (SD 1.7) (p=0.004). This 
improvement was sustained during long term follow up with HbA1c at follow up 
with a mean of 6.0 years (median 4.5; P25-P75 : 2.3-11.1) being 8.6% (SD 1.6) 
(p=0.001 vs. baseline). 
BMI 
BMI could be calculated both before and on CIPII of 26 patients. Mean BMI did not 
increase significantly from 24.4 (SD 4.0) before CIPII to 25.1 (SD 4.3) on CIPII 
(p=0.46; median 3.5 years after implantation, P25-P75 : 1.9-12.9). 
Self reported variables (see Table 3) 
73% reported no hospital admissions related to their diabetes in the year preceding 
the questionnaire. Median number of daily blood glucose measurements was 5 
(P25-P75 : 4-7). 87% perceived a better glycaemic regulation on CIPII as compared to 
previous insulin treatment modalities. 67% perceived less hypoglycaemic incidents 
with CIPII. 
One or more macrovascular complications (myocardial infarction, angina, coronary 
artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), 
stroke or intermittent claudication) were reported by 23% (n= 7). 47% (n=14) 
reported having hypertension. 
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Table 3. Patient report on hospital admission, self control of blood glucose, 
macrovascular complications, glycaemic control and hypoglycaemic events 
Variable n Variable n 
Number of hospital Self control of blood 
admissions in last year glucose (times/day) 
diabetes related 1-5 14 
0 22 5-10 14 
1 3 > 10 1 
2-4 3 Not recorded 1 
� 5 2 
non-diabetes related Macrovascular complications 
0 20 Yes 7 
1 5 No 20 
2-4 4 Do not know 2 
� 5 1 Not recorded 1 
Day time hypoglycaemic Night time hypoglycaemic 
events (n/4 weeks) events (n/4 weeks) 
0 5 0 16 
1-5 9 1-5 10 
5-10 10 5-10 1 
� 10 5 � 10 1 
Not recorded 1 Not recorded 2 
Perceived better glycaemic Perceived less hypoglycaemic 
control with CIPII events with CIPII 
Yes 26 Yes 20 
No 1 No 1 
No difference 2 No difference 8 
Not recorded 1 Not recorded 1 
Health status and patient satisfaction 
Due to missing answers, the SF-12 scores from 2 out of 30 patients could not be 
calculated. SF-12 PCS was 37.4 (SD 12.1) and SF-12 MCS was 47.2 (SD 11.1). Mean 
score on the WHO-5 was 52.7 (SD 28.6) (n=30). Median score for treatment 
satisfaction was 32 (P25 -P75 : 28-36; n=28). 
There where no differences between men and woman regarding scores on SF-12, 
WHO-5 or DTSQ (p>0.1). 
- -------- ---
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Discussion 
With this present study we report details regarding a population of Dutch patients 
with diabetes mel l itus treated with CIPII and cared for in a single centre in The 
Netherlands. Data were assessed regarding glycaemic control ,  health status, wel l­
being and treatment satisfaction. 
Most available research done with CIPII is conducted in either France or the U.S.A. 
Up til l now there are no prospective randomised trials with CIPII performed in The 
Netherlands. 
Our results concerning glycaemic control and quality of life are consistent with the 
results presented by De Vries et al in 2002 who studied part of the population 
presented in this article. Twenty of 33 patients in their analysis were treated in our 
hospital at that time.[18] Our report provides further evidence on the long-term 
efficacy of CIPII regarding glycaemic control and hospital admissions with a mean 
fol low up of 6.0 years. In addition to De Vries et al, we report now on treatment 
satisfaction and well-being. 
Our results regarding current health status of patients with diabetes mel l itus 
treated with CIPII are comparable with health status of patients with diabetes 
mel litus and comorbidity as reported by Rijken et al.[28] Compared with the 
general Dutch population as reported by Gandek et al , the SF-12 MCS of our 
population is lower. [22] 
The mean score on the WHO-5 in our population is much lower than the mean 
score of around 70 in the general population.[23] The cut-off point for further 
testing for depression is a score below 50 (raw score below 13). When applying this 
cut-off point to our data, 39% of our population has an indication for further 
testing (n=13). The percentage of patients scoring below the cut-off point on the 
WHO-5 is higher in our population then the percentages reported by Rakovac et al 
for patients with type 1 and type 2 diabetes, 23% and 30.9% respectively.[29] 
However, due to the smal l  population size in our study, this difference may be 
based solely on a sampling error. 
The high level of satisfaction with treatment in our study is comparable with the 
treatment satisfaction levels  reported for CSII and MDI by Hoogma et al. [27] Home 
et al reported baseline treatment satisfaction levels of type 1 diabetes mel l itus in 
their randomised control led trial comparing insulin aspart with human insulin that 
are also similar to our levels.[30] Although ceiling effects of the questionnaire used 
have been raised as a point of concern [31] , this wil l  pose less of a problem in a 
cross-sectional measurement.[32] To assess future satisfaction, use of the 'Change 
version' of the questionnaire might be appropriate.[32] 
Based on these data we conclude that although treatment satisfaction with CIPII is 
high and very similar to treatment satisfaction of type 1 diabetes mel litus patients 
on MDI or CSII, mental health status and wel l-being of this population are lower 
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than for other treatment modalities. We can only hypothesize about the 
determinants of these low scores. There is some evidence for the association of 
duration of diabetes and being female with decreased quality of life, which may 
partly explain the results found in our study.[33] Mean duration of diabetes at the 
time of the study was almost 25 years and the percentage female almost 80%. We 
are not properly informed about the nature and occurrence of physical complaints 
and microvascular complications in our population; these complications will have a 
negative impact on well-being and health status.[34] Furthermore, we do not know 
the coping behaviours and personality characteristics of our patients, parameters 
known to influence quality of life.[35] 
Study limitations 
The retrospective design is the main limitation of our study. Data on hospital 
admissions and macrovascular disease were based on self report and this could 
potentially be a study limitation. Furthermore, we do not have baseline scores for 
health status, well-being and treatment satisfaction. 
In conclusion, based on our data, CIPII does improve glycaemic control without 
increasing the risk of hypoglycaemic events. Furthermore, treatment satisfaction 
with CIPII is high and in the same range as treatment satisfaction with other 
intensive treatment modalities. Mental health status and well-being of the patients 
studied were low, with further investigation regarding depression probably being 
appropriate in 1 out of 3 patients. 
Up till now, CIPII is still a last resort treatment in The Netherlands. Most patients are 
concentrated in one clinic. The consequence is that eligible patients have to travel 
sometimes great distances for evaluation, implantation, refilling and emergencies 
concerning CIPII. Data on the performance of CIPII in France suggest that CIPII 
would be an effective treatment option for more patients with diabetes mellitus. 
Almost all the evidence we have on CIPII comes from French or American studies 
on the subject. We think there is a need for evidence from other countries where 
this treatment modality is used. 
At this moment, a randomised cross-over clinical trial is conducted in our centre to 
provide information about the safety and efficacy of CIPII in patients with diabetes 
mellitus type 1 and poor glycaemic control. Results of this study will help to answer 
the question whether CIPII is a safe and effective treatment option for diabetes 
mellitus. 
�----
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Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump is safe 
and effective in selected subjects with diabetes. Our aim was to assess surgical 
experience and complications with CIPII. 
Methods 
We performed a retrospective longitudinal observational cohort study of patients 
that started with CIPII from 1990 to 2006. Operation free period and complication 
rate were compared between patients initiating CIPII before 2000 and from 2000 
onwards. 
Results 
In 63 patients, 166 re-operations were performed during 381 patient-years. Re­
operations were; pump replacement due to end-of-battery-life (47%), laparoscopic 
catheter-related procedures (29%) and other interventions (24%). Median operation 
free period increased from 21 to 78 months from 2000 onwards (p=0.039). 19% of 
patients developed complications. No operation-related mortality was reported. 
Conclusion 
Increased experience together with technical improvements has led to an increase 
of the operation free period. The absence of procedure related mortality and a low 
complication rate make CIPII feasible for selected patients with diabetes. 
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Introduction 
Continuous intraperitoneal insulin infusion (CIPII) with an implantable insulin pump 
has been available as a treatment option in patients with diabetes mellitus for more 
than 25 years already. Its safety and efficacy has been reported by the EVADIAC 
study group and others. [1-6] Better glycaemic control in terms of lower HbA1c, 
decreased number of hypoglycaemic events and reduced glycaemic variability can 
be achieved and patients' treatment satisfaction is high.[1-8] This therapy mode is 
only available in a limited number of countries where CIPII is mainly used in 
patients who, despite intensive (continuous) subcutaneous insulin therapy, do not 
reach acceptable glycaemic control and/or have frequent hypoglycaemic episodes 
(especially when accompanied by hypoglycaemia unawareness) and/or have 
subcutaneous insulin resistance. 
Studies focusing on the surgical aspects of CIPII are relatively scarce. Udelsman et 
al. reported regarding 21 patients started on CIPII between 1986 and 1991 in an 
American centre needing 1 surgical re-intervention per 1.7 patient-years without 
occurrence of mortality.[9] This group published an update in 2000 reporting the 
same rate of re-interventions in 28 subjects.[10] At the time of these reports, the 
pump battery lasted approximately 2.5 years and many re-interventions were 
needed because of the necessity of pump replacement after battery depletion.[9] 
One re-intervention per 10.9 patient-years was related to catheter problems.[9] 
Three times a pump was explanted because of pump-site infections during a total 
of 153 patient-years (1 in 51 patient-years).[9] Others reported incidences of pump­
site infection of 1 per 53 and 56 patient-years and of re-intervention because of 
catheter problems or electronic failure of 1 per 22 patient-years, respectively.[11,12] 
All above discussed reports contain only patients included before 2000. However, 
since then, many innovations have been made. Battery life is increased to a 
maximum of 7 years and the insulin solution used nowadays results in reduced 
incidence of insulin aggregate formation, and thereby less catheter 
obstructions.[13] The purpose of this study is to describe the surgical implications 
and complications in a large group of patients treated with CIPII in the Netherlands. 
Furthermore, we studied whether increased experience with the procedure and 
improvements to the pump in 2000 led to a decreased necessity for re-intervention 
surgery. 
Material and methods 
Patients 
Patients were selected for CIPII after consultation with the diabetes team consisting 
of an internist and a diabetes specialist nurse. Indications for CIPII are failure to 
reach adequate glycaemic control despite intensive insulin therapy with multiple 
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daily injections or continuous subcutaneous insulin infusion, and/or having 
frequent hypoglycaemic episodes (especially when accompanied by hypoglycaemia 
unawareness) and/or having subcutaneous insulin resistance. Implantation was 
always combined with intensive education and on indication with assessment by a 
psychologist. 
All patients who received their first implantable insulin pump for CIPII between 
1990 through 2006 were included in the study and retrospectively analyzed. All 
patients on CIPII in the Netherlands are implanted in one hospital; Isala clinics, 
Zwolle. Glycaemic control, health status and treatment satisfaction of this patient 
group have been described previously.[7] Patient data were retrieved from clinical 
and surgical reports. 
Insulin pump 
In our clinic, the MiniMed MIP 2001 (Medtronic-MiniMed, Northridge, CA, USA) 
was implanted since the 1980's. This model had a lithium cell battery with a battery 
life of approximately 2.5 years. From 2000 onwards, the MIP model 2007, with a 
battery life of approximately 7 years, is used for all implantations and replacements. 
Both models have a reservoir to contain up to 15 ml U400 insulin which is 
maintained at negative atmospheric pressure. The pump has a diameter of 8 cm 
and is 2 cm thick. The 2007 model is slightly lighter (131 grams, without insulin) 
than the previous model (145 grams). 
A silicone catheter is attached to the side port of the pump, through which the 
insulin is delivered directly into the peritoneal cavity. Insulin delivery is remotely 
controlled by the patient with a pager-sized personal pump communicator. 
Implantation and postoperative treatment 
Before pump implantation, the endocrinology team filled and primed the pump on 
a sterile table in the operating theatre. This means, that when the pump is handed 
to the surgeons it is immediately functional. 
After induction of general anaesthesia, a first generation cephalosporin is 
administered intravenously. The abdominal skin is carefully cleaned with 
chlorhexidin and a sterile plastic is draped on the skin. A transverse incision is made 
in an abdominal quadrant, selected pre-operatively by the patient and the diabetes 
specialist nurse. After dissection of the subcutaneous tissue a subcutaneous pocket 
is created. Thereafter, to create an entrance to the intraperitoneal cavity for the 
catheter, the anterior fascia of the rectus abdominis is incised, the fibres of the 
rectus muscles are spread and the posterior rectus sheath is opened. The 
peritoneum is opened and the tip of the catheter is carefully inserted and directed 
to the right upper quadrant or the Douglas pouch of the peritoneal cavity. A purse­
string suture is placed on the peritoneum and the flange is sutured just behind the 
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anterior rectus fascia. The pump is sutured into the subcutaneous pocket after 
placing a gentamicin gauze (Figure 1). The wound is closed in layers. 
Figure 1. Insulin pump and catheter in vivo 
,-.. .:,..�'-"'--:,:---.,.....__......,.._ __ refill port 
-------- flange --->--�rn.1 1  
Schematic representation of  the  position of the  insu l i n  pump and  catheter i n  vivo. 
Postoperatively, to minimi:z;e pain and the development of pump-pocket seroma, 
24 hours strict bed rest is maintained and a supportive belt is prescribed for 4-6 
weeks. Furthermore, patients are instructed not to lift heavy weights and not to 
engage in strenuous physical exercise during the first 6 weeks after surgery. In 
general, patients are discharged from the hospital on the 3 rd or 4th post-operative 
day, depending on the ability and confidence of the patient to use the implantable 
pump. 
Refill & Rinse procedures 
The pump insulin reservoir is refilled at the outpatient clinic transcutaneously at 
least every 3 months, depending on the individual's insulin requirement. 
Obstruction by insulin aggregation in the pump or catheter can be treated with 
rinse procedures. Buffer and/or NaOH alkaline solution (0.lM) is flushed through 
the pump or separately through the catheter, using the side port. Performing these 
procedures on a regular basis can partly prevent total blockage of the system by 
removing the partial stenosis caused by insulin precipitation. Since recently 
changing protocols, rinse procedures are carried out every 9 months or when 





Pump-site infection was defined as a culture proven infection in the subcutaneous 
pocket of the insulin pump. Prolonged pain was defined as pain of the pump-site 
which lasted for more than 6 weeks after surgery. Cutaneous erosion of the skin 
was defined as redness with signs of imminent perforation of the overlying skin at 
the pump-site. Postoperative haematoma was defined as a swelling at the pump­
site caused by rebleeding. Small postoperative seromas were not classified as a 
complication as it always had a mild presentation which resolved completely in all 
cases without re-intervention. 
Statistical analysis 
Descriptive statistics include number (percentage), mean (standard deviation (SD) 
and median (interquartile range). Patient characteristics were compared with the 
Chi-square test in case of categorical data, and in case of continuous data Student's 
T-tests (normal distribution) or Mann Whitney-LI test in case of skewed data. Q-Q 
plots were performed to determine whether the data had a normal distribution. For 
comparison of the operation free period the log-rank test was used with 
construction of Kaplan-Meier curves for visualisation. A Cox regression analysis was 
performed to study the influence of possible confounders (age, sex, BMI, duration 
of diabetes, the presence of retinopathy, neuropathy and nephropathy). A p-value 
of less than 0.05 was considered statistically significant. 
Results 
Patients & procedures 
Between 1990 through 2006, 63 patients were treated with CIPII and all are 
included in our analyses. Patient characteristics are shown in Table 1. Mean age at 
first pump implantation was 38 (14) years, 47 (75%) patients were female and most 
had type 1 diabetes mellitus (58 patients; 92%). Notably, more microvascular 
complications were present in patients with an implantation before 2000. 
In 381 patient-years, 1 re-intervention per 2.3 patient-years was performed. A new 
insulin pump was implanted in 78 (47%) cases, due to expected end-of-battery-life. 
In 32 (19%) cases laparoscopy was performed during which a fibrin plug could be 
removed from the catheter tip to resolve pump dysfunction. In 17 (10%) cases the 
whole catheter was replaced to resolve pump dysfunction due to obstruction by 
insulin crystals. Pump removal was performed in 21 (13%) cases for several reasons. 
Other operations were performed 18 (11 %) times, including moving the pump to 
another side because of infection or pain, and removal of haematoma (see table 2). 
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Table 1. Patient characteristics at start of CIPII 
Implantation date 
Before 2000 In or after 2000 
n=28 n=35 
Age (years) 1 38 (12) 37 (15) 
Fema le sex 19 (68) 28 (80) 
Type 1 d iabetes 23 (82) 34 (97) 
Duration of diabetes (years) 2 17 (12-21) 15 (9-26) 
BMI (kg/m2) 1 25.0 (4.8) 26.2 (4.7) 
Nephropathy 5 (18) 2 (6) 
Neuropathy 16 (57) 7 (20)** 
Retinopathy 15 (54) 10 (29)* 
Values are number of patients (percentages) unless indicated otherwise, 1 mean (SD) or  2 
median (interquarti le range) . CIPII= Continuous Intraperitoneal Insu l in  Infusion. * p-va lue of 
comparison between groups < 0.05, ** p-value of comparison between groups <0.01 
Table 2. Surgical procedures and complications during follow up 
Tota l patient years 
Surgical Procedures 
Al l  
New pump implantation 
Laparoscopy 
Catheter replacement 




























































Va lues a re number of procedures or compl ications (percentage of total procedures or  
compl ications in  g roup) 
43 
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Operation free period 
In order to investigate whether the operation free period increased with our 
increasing experience with pump implantation and increased battery durance, we 
divided our population in two groups, i.e. patients implanted before 2000 (n=28) 
and in or after 2000 (n=35). Patients underwent a median number of 2 (1-6) 
operations. We calculated the median operation free period between the first and 
second operation. This operation free period increased from 21 (95% confidence 
interval (Cl): 10-33) months for patients operated initially before 2000 to 78 (95% 
CI: 13-79) months for patients operated in or after 2000 (p=0.039; log-rank test, see 
Figure 2). After excluding operations for pump replacement after expected battery 
end-of-life, this difference remained statistically significant (p=0.048). 
Figure 2. Time between first and second operation in patients on CIPII before 









Operated before 2000 
Patients at risk 28 
Events 0 
Operated after 2000 
Patients at risk 35 
Events 0 





Time between first and second operation 
24 36 










Kaplan-Meier curve from start of CIPII to first consecutive intervention. Closed squares 
indicate patients initially operated before 2000; open squares indicate patients initially 
operated in or after 2000. CIPII = Continuous Intraperitoneal Insulin Infusion 
The Cox regression analysis showed that patients implanted in or after 2000 had a 
hazard that is nearly halve (hazard ratio (HR) = 0.46, 95% CI: 0.21-1.00) of that for 
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those who were implanted before 2000. None of the confounders had a significant 
relation with time to first re-intervention. After excluding operations for pump 
replacement after expected battery end-of-life, the HR dropped to 0.28 (95% CI: 
0.09-0.82; p=0.020). (See Table 3) 
Table 3. Cox regression. Time between first and second operation in patients 
started on CIPII before compared to in or after 2000, corrected for confounders 
Hazard Ratio p-value 95% CI for Hazard Ratio 
Lower Upper 
Implanted in or after 2000 0.46 0.05 0.21 1.00 
Female sex 0.52 0.17 0.20 1.33 
Age (years) 0.98 0.30 0.95 1.02 
BMI (kg/m2) 1.03 0.41 0.96 1.12 
Duration of d iabetes (years) 1.02 0.40 0.97 1.07 
Presence of ret inopathy 1.98 0.20 0.70 5 .59 
Presence of  nephropathy 0.87 0.83 0.25 3 .02 
Presence of neuropathy 0.60 0.34 0.21 1.70 
Complications 
Twelve patients (19%) developed 19 complications, of which local infection and 
pain were most common (Table 2). Nine (1 in 3 .1 patients) complications developed 
before 2000 and 10 (1 in 3.5 patients) after 2000. Five patients developed 9 pump­
site infections in the postoperative period, from 2 weeks till 5 months after 
implantation. Four infections appeared before 2000 (1 in 73.5 patient-years) and 5 
infections in and after 2000 (1 in 17.4 patient-years), in which period 1 patient had 
4 episodes of infection. In 2 cases the pump was removed and re-implanted in a 
new pocket on the opposite side of the abdomen after complete resolvement of 
the infection, in 1 patient with good success. Unfortunately, in the other patient, a 
recurrent pump-site infection occurred for 3 more times and this led to the 
decision to completely discontinue CIPII treatment. In another patient, pump-site 
infection was also treated with pump removal. Because to date the infection has 
not settled yet, a new pump is not implanted yet and the patient is on intravenous 
insulin infusion in the meantime. Pump-site infection was treated in 2 patients with 
percutaneous flushing of the pocket with antibiotics, after which CIPII could be 
continued without further complications in 1 of these patients; in the other patient 
this procedure was not successful, so the pump was removed and re-implanted 
after complete recovery of the infection. Six patients developed prolonged pain 




In 1 patient slight relocation of the pump within its pocket, and in 2 patients 
relocation to a new pocket were successful in alleviation of symptoms. Pain was 
relieved in 1 patient with laparoscopy, during which several adhesions were cut. In 
3 patients cutaneous erosion of the overlying skin was seen. In 1 patient the pump 
was moved to another quadrant of the abdomen; 2 other patients had very little 
subcutaneous fat, so we moved the pump under the fascia of the rectus abdominis. 
This led to a satisfactory situation, although refill and rinse procedures were more 
painful due to this alternative location. Local anaesthesia with lidocaine is therefore 
used during these procedures. In 1 patient a postoperative haematoma was 
removed from the pocket, after which CIPII was continued without further 
complications. 
Mortality and cessation of CIPII 
During the follow-up period 6 patients died; none of the deaths were related to 
postoperative or pump-related complications. Five patients died of diabetes related 
complications; due to kidney (n=3) or heart failure (n=2); 1 of mesenteric ischaemia 
while treated with CIPII. 
In 11 patients, CIPII was stopped and the pump removed. In 2 patients the pump 
was removed because of recurrent infections, as described above. In other cases 
CIPII was discontinued because of pump failure (n=3), inadequate glycaemic 
control (n=3), kidney-pancreas transplantation (n=2) and psychological reasons 
(n=l). 
Discussion 
This study shows that during more than 15 years of experience with CIPII in our 
centre the operation free period of these patients increased from 1.8 years to 6.5 
years, and is currently almost at its maximum. Ideally, only 1 procedure in 7 patient­
years is needed to replace the pump when the battery has been depleted. This 
increase can mainly be attributed to the increased battery durance of the insulin 
pumps, and the standardization of rinse procedures, preventing the accumulation 
of insulin aggregates to cause pump malfunction. Our current report shows that 
despite the requirement of re-intervention surgery during follow-up, CIPII is safe, 
without pump or operation related mortality and with a low complication rate. 
More than 80% of our patients has not experienced any pump related 
complications and our pump-site infection rate of 2.4 per 100 patient-years is 
comparable with that in l iterature.[10,12,13] This infection rate was higher in the 
patients operated in or after 2000 (1 in 73.5 versus 1 in 17.4 patient-years). 
However, this is mainly due to 1 patient operated after 2000 who developed 4 
pocket-site infections. This infection rate compares favourably with that of other 
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implanted devices, like implantable defibrillators or mechanical heart valves with a 
reported infection rate of 2.5-4.0 per 100 patient-years.[14,15] 
The most important drawback of CIPII is the high costs of this kind of treatment. 
Not only the pump itself, which currently costs approximately 36.000 Euros, but 
also the special insulin used and the need for regular filling and rinsing procedures 
performed by diabetes specialist nurses during outpatient sterile procedures, make 
CIPII a very costly treatment option. Whether or not this treatment can be cost­
effective compared to external insulin pump therapy, when long term diabetes 
complications, prevented hospital admissions and loss of workdays are taken in to 
account, remains to be investigated. The only cost analysis with CIPII up to now was 
done by Haardt et al. more than 15 years ago.[16] Compared to multiple 
subcutaneous injections direct costs of CIPII were 2.6 fold higher.[16] 
As far as we know, this study reports on one of the largest groups of patients 
treated with CIPII in a single centre with a follow-up exceeding 15 years. Only the 
French EVADIAC collaborative has a combined experience that exceeds the 
presented one.[13] 
Our study has its limitations. Its retrospective design might lead to an 
underestimation of the complication rate. However, we systematically analyzed 
hospital and operation records of all patients that received CIPII in the studied 
period in our hospital. Due to the intensive contact patients have with the diabetes 
team, it is highly unlikely that any cases are missing in the current report. On the 
other hand, many of the pumps that were implanted after 2000 are still functioning 
without the need for re-intervention yet, possibly resulting in an overestimation of 
the reported re-intervention rate in that group. 
Conclusion 
Increased experience with CIPII in our centre together with technical improvements 
of the pump has led to an almost 4-fold increase of the operation free period. The 
operation free period is almost at its maximum and is currently mostly limited by 
pump battery life. The absence of pump or operation related mortality and the 
relatively low complication rate make CIPII a feasible treatment alternative for 
selected patients with diabetes that cannot reach adequate glycaemic control with 
other intensified insulin regimens. 
Acknowledgements 
We wish to thank Dr Evert van Ballegooie for his continuing support for this patient 





J4s L _ _  
Surgical aspects and complications of CIPII - retrospective study 
References 
1. Dunn FL, Nathan DM, Scavin i  M et a l . :  The Implantable Insu l in Pump Tria l  Study G roup. 
Long-term therapy of IDDM with an implantable insu l in pump. Diabetes Care 
1997;20:59-63 
2. Nathan DM, Dunn FL, Bruch J et a l .  Postprandia l  insu l i n  profi les with implantable pump 
therapy may expla in decreased frequency of severe hypoglycemia, compared with 
intensive subcutaneous reg imens, i n  insu l in-dependent diabetes mel l itus patients. Am J 
Med 1996;100:412-17 
3. Schade DS, Eaton RP, Spencer W. Norma l ization of p lasma insu l in  profi les in diabetic 
subjects with programmed insu l in del ivery. Diabetes Care 1980;3:9-14 
4. Selam J L, Micossi P, Dunn FL et a l .  C l inical tria l of programmable implantable insu l in 
pump for type I diabetes. Diabetes Care 1992;15:877-85 
5. Broussol le C, Jeandid ier N ,  Hanaire-Broutin H :  The EVADIAC Study Group. Evaluation of 
Active Implants in Diabetes Society. French mu lticentre experience of implantable 
insu l i n  pumps. Lancet 1994;343:514-5 
6. Saudek CD, Duckworth WC, Giobbie-Hurder A et al.: Department of Veterans Affa i rs 
Implantable Insu l in  Pump Study Group. Implantable insu l in  pump vs mu ltiple-dose 
insu l i n  for non-insu l in-dependent diabetes mel l itus: a randomized cl inical trial . JAMA 
1996;276:1322-7 
7. Logtenberg SJ, van Bal legooie E, Israel-Bu ltman H et a l .  G lycaemic control, hea lth status 
and treatment satisfaction with continuous intraperitoneal insu l i n  infusion. Neth J Med 
2007;65:65-70 
8. Selam J L, Raccah D, Jean-Didier N et al. Randomized comparison of metabol ic control 
achieved by intraperitoneal insu l in infusion with implantable pumps versus intensive 
subcutaneous insu l in therapy in type I diabetic patients. Diabetes Care 1992;15:53-8 
9. Udelsman R, Chen H, Loman K et a l .  Implanted programmable insu l in pumps: one 
hundred fifty-three patient years of surg ica l  experience. Su rgery 1997;122:1005-11 
10. Udelsman R, Boyne MS, Loman KE et al. Intraperitoneal del ivery of insu l in via 
mechanical pump: surgical impl ications. Langenbecks Arch Surg 2000;385:367-72 
11. Thompson JS, Duckworth WC, Saudek CD et al . :  Depa rtment of Veterans Affairs 
Implantable Insu l in Pump Study Group. Surgica l experience with implantable insu l in  
pumps. Am J Su rg 1998;176:622-6 
12. Gin H, Renard E, Melki V et a l .  Combined improvements in implantable pump 
technology and insu l in  stabi l ity a l low safe and effective long term intraperitonea l 





13. Renard E, Schaepelynck-Belicar P. Implantable insulin pumps. A position statement 
about their clinical use. Diabetes Metab 2007;33:158-66 
14. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 
2004;350:1422-9 
15. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients 
with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83 
16. Haardt MJ, Selam JL, Slama G et al. A cost-benefit comparison of intensive diabetes 
management with implantable pumps versus multiple subcutaneous injections in 








Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump has 
been available for the past 25 years. CIPII, with its specific pharmacodynamic 
properties, may be a viable treatment alternative to improve glycemic control in 
patients with type 1 diabetes for whom other therapies have failed. There have 
been few studies in which CIPII was compared with subcutaneous (SC) insulin 
treatment for patients with type 1 diabetes with poor glycemic control. 
Research Design and Methods 
In an open-label, prospective, crossover, randomized, 16-month study, the effects 
of CIPII and SC insulin were compared in 24 patients. The primary outcome 
measure was the incidence of hypoglycemia. Secondary outcome measures were 
glycated hemoglobin (HbA1c), and glucose profile, including time in euglycemia, as 
measured by continuous glucose monitoring. 
Results 
The incidence of grade 1 hypoglycemic events was 4.0±2.6 per week with SC insulin 
compared with 3.5±2.3 per week during CIPII (p=0.13). The absolute mean 
difference in HbA1c with CIPII as compared with SC treatment was -0.76% (95% CI:-
1.41,-0.11) (p=0.03). Baseline time spent in euglycemia was 45.2±12.6% and 
increased 10.9% (95%CI:4.6,17.3) with CIPII compared to SC treatment (absolute 
value; p=0.003). There were no differences in the occurrence rate for severe 
hypoglycemic events, daily insulin use, or BMI. No pump or catheter malfunction 
was observed during the study. 
Conclusions 
Though we did not observe a significant reduction in hypoglycemic events, 
improved glycemic control was achieved with the use of CIPII. We saw a 0.8% 
decrease in HbA1c and an 11% increase in the time spent in euglycemia. 
Glycemic control with CIPII - prospective study 
Introduction 
Meta-analyses conclude that continuous subcutaneous insulin infusion (CSII) is 
somewhat better than multiple daily injections (MDI) for obtaining glycemic control 
in patients with type 1 diabetes.[1-4] . These differences tend to be smaller when 
synthetic analogues are used. The absorption of subcutaneous (SC) infused insulin 
is influenced by many factors, sometimes responsible for unexpected hypo- and 
hyperglycemic events.[5,6] In some patients with type 1 diabetes, this form of 
therapy does not yield acceptable and stable long-term glycemic control.[7] 
The intraperitoneal administration of insulin allows blood glucose values to 
normalize more rapidly after a meal with more predictable insulin profiles 
compared to SC insulin.[8-10] . Much of the intraperitoneal insulin is absorbed 
through the portal system, which more closely mimics normal physiological action, 
resulting in improved hepatic uptake and lower peripheral plasma insulin levels.[11] 
This may lead to improved glucagon secretion and hepatic glucose production in 
response to hypoglycaemia.[12] 
The effects of continuous intraperitoneal insulin infusion (CIPII) in type 1 diabetes 
have been investigated in few randomized controlled trials, and all were done 
before the era of rapidly acting insulin analogues. The objective of our study was to 
assess the safety and efficacy of CIPII compared to intensified SC insulin therapy in 
patients with inadequately controlled type 1 diabetes. 
Research Design and Methods 
Study Population 
Subjects with type 1 diabetes with low fasting c-peptide concentrations ( < 0.20 
nmol/L), with intermediate or poor glycemic control, defined as glycated 
hemoglobin (HbA1c) � 7.5% and/or �5  incidents of hypoglycemia ( < 4.0 mmol/L) per 
week, aged 18 to 70 years, treated with MDI or CSII, were eligible for the study. The 
exclusion criteria included: impaired renal function (plasma creatinine �150 µmol/L 
or glomerular filtration rate as estimated by the Cockcroft-Gault formula � SO 
ml/min)[13] ;  cardiac problems (unstable angina or myocardial infarction within the 
previous 12 months or New York Heart Association class III or IV congestive heart 
failure); insulin allergy; mentally handicapped, current or past psychiatric treatment 
for schizophrenia, cognitive or bipolar disorder; severe untreated proliferative 
retinopathy; current use of oral corticosteroids or suffering from a condition which 
necessitated oral or systemic corticosteroid use more than once in the previous 12 
months; substance abuse, other than nicotine; a history of cancer, excluding well 
differentiated thyroid carcinoma, breast carcinoma without lymph node metastases, 
and skin carcinoma; and plans to engage in activities that require going > 25 feet 





The study has a crossover, randomized design and was conducted at a single 
center (lsala Clinics, Zwolle, The Netherlands). The study consisted of 4 phases: the 
qualification phase, the first treatment phase, the crossover phase, and the second 
treatment phase. During the three month qualification phase, the patients' pre­
study diabetic therapy was used to attempt optimization of their glycemic control. 
The patients were then randomly allocated to one of two groups, which differed 
only in the sequence of the two therapies. Randomization was performed in blocks 
of 4. 
Insulin (U400 semi synthetic human insulin of porcine origin; Hoechst, Frankfurt, 
Germany, recently Sanofi-Aventis) was administered with an implanted pump (MIP 
2007C, Medtronic/Minimed, Northridge, CA, USA). The CIPII pump was implanted 
under general anesthesia at the start of the CIPII phase in all subjects. Figure 1 is a 
schematic representation of the pump and its location. For subjects who received 
SC insulin during the second treatment phase, the CIPII pump was filled with an 
inert fluid at the end of the first treatment phase. SC insulin was delivered with 
either MDI or CSII, according to what was used prior to the study. 
Both treatment phases were 6 months in duration. A crossover phase of 4 weeks 
was instituted in between to minimize carryover effects of CIPII. During the 
crossover phase, insulin was administered subcutaneously. 
After completion of the trial, subjects were given the option of continuing with 
their preferred mode of therapy. 
Figure 1. Schematic view of the position of the insulin pump and catheter in vivo 
Glycemic control with CIPII - prospective study 
Patients monitored their own glucose levels (SMBG; One Touch Ultra, LifeScan, 
Milpitas, CA, USA) four times every day (fasting, before meals, bedtime), and 7 
times daily 2 days per week (fasting, before and after meals, bedtime). If nocturnal 
hypoglycemia was suspected, subjects would perform an additional blood glucose 
measurement between 2 and 3 AM. Furthermore, subjects recorded all episodes of 
hypoglycemia grade 1, defined as glucose <4.0 mmol/L, grade 2, defined as 
glucose < 3.5 mmol/L, and grade 3, which is defined as the patient requiring third 
party help and/or losing consciousness, or requiring intravenous glucose or 
glucagon treatment. To limit the risk of data-entry error, the data from the SMBG 
meters were downloaded to a computer during every clinic visit. 
Twice per month, the study subjects were in contact with a nurse specialized in 
diabetes, alternating telephone and clinic visits. The subjects were in contact with 
the medical team as necessary. 
If the subject was using more than 40 IU of SC insulin per day prior to starting the 
CIPII phase of the study, his or her starting dose was set at 90% of the prior SC 
dose. Subjects using less than 40 IU of SC insulin received a starting dose of 80% of 
the prior SC dose. Initially, the dose was equally divided between a basal rate (50%) 
and a bolus before meals. During all study visits, the 7-point glucose readings were 
used to adjust the dose regimen if necessary to achieve pre-prandial glucose levels 
between 4.0-7.0 mmol/L and post-prandial levels between 4.0-9.0 mmol/L. 
The study was performed in accordance with the Declaration of Helsinki. Informed 
consent was obtained from all patients, and the protocol was approved by the 
Medical Ethics committee of the Isala Clinics in Zwolle. 
Measurements 
Demographic and clinical parameters were recorded at baseline. These data 
included smoking and alcohol habits; year of diagnosis of diabetes; the presence of 
complications; any co-morbidity; and height and weight. The HbA1c level was 
measured at baseline, at the end of the qualification phase, and at the start, halfway 
and at the end of both treatment phases with a Primus Ultra2 using high­
performance liquid chromatography (reference value 4.0-6.0%). In addition, 5 -7 day 
24-hour blood glucose profiles were recorded with a continuous glucose 
monitoring (CGM) system (CGMS, Medtronic/Minimed, Northridge, CA, USA) at 
baseline, at the halfway point and at the end of both treatment phases. Time spent 
in the hypoglycemic range was defined as percentage of CGM recordings of < 4.0 
mmol/L; time spent in euglycemic range was defined as percentage of CGM 
recordings from 4.0 to 10.0 mmol/L, and time spent in hyperglycemic range was 




Primary and secondary outcomes 
The primary outcome was the incidence of hypoglycemic episodes. The secondary 
outcome was glycemic control (as indicated by HbA1c levels). Other pre-specified 
outcomes included time spent in hypo-, eu- and hyperglycemia, daily insulin usage, 
adverse events, and device complications. 
Adverse events of CIPII and device complications were subdivided according to the 
following categories: Pump-malfunction, including catheter obstruction; pump-site 
infection, defined as a culture proven infection in the subcutaneous pocket of the 
insulin pump; prolonged pain, defined as pain at the pump-site, which lasted for 
more than 6 weeks after surgery; cutaneous erosion of the skin, defined as redness 
with signs of imminent perforation of the overlying skin at the pump-site; 
postoperative hematoma, defined as a swelling at the pump-site caused by 
(re)bleeding. 
Statistical analysis 
The incidence of hypoglycemia grade 1 in potentially eligible patients at our clinic 
of 3.7±2.2 per week was used for sample size calculation. To be able to detect a 
30% decrease in hypoglycemic events with a power of 0.80 and a two-sided alpha 
of 0.05, 34 patients would be needed. To compensate for non-evaluable patients, 
the initial goal was to enroll 40 patients. 
Descriptive summaries included the mean (± standard deviation (SD) or standard 
error (SE)) for normally distributed variables and the median with the interquartile 
range (IQR) for other variables. Time variables, such as times spent in the different 
glycemic states are presented as absolute values. Normality was examined using Q­
Q plots. Planned analyses were conducted to address the study objectives as 
defined, using a nominal significance level of 0.05. General linear models were used 
to test differences, taking the order of the two treatments into account. To 
calculate the mean difference with a 95% confidence interval (Cl) the Hills-Armitage 
approach was used, which accounts for any period effect.[14,15] If assumptions for 
the general linear models were not met, non-parametric tests were used, without 
obtaining a 95% CL Statistical analyses were performed with SPSS software, 
versions 15.0 and 16.0. All reported P values are two-sided. 
Results 
Patients 
Of 50 patients who were screened, 25 entered the qualification phase, after which 1 
patient was excluded as having attained acceptable glycemic control. Therefore, 24 
patients were randomized and started the first treatment phase between June 2006 
and March 2007; 12 patients were assigned to start with SC insulin and 12 patients 
to start with CIPII during the first phase (Figure 2). 
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Figure 2. CONSORT (Consolidated Standards of Reporting Trials) flowchart 
I 50 patients were assessed for eligibility I 
24 did not meet entry criteria 1 4  refused to participate 10 did not meet inclusion criteria 
� 4 had good glycemic control 2 were trying to conceive 1 had ps)'Chiatric illness 3 had other exclusion criteria 
� 
1 did not enter qualification phase due to unavailability of IP-pump 
,, 
I 25 entered qualification phase I 1 was excluded -. - reached acceptable glycemic control at the end of qualification 
24 were randomized I 
• • 
1 2  allocated to receive IP 12  allocated to receive SC 
treatment in 1 st phase treatment in pt phase 1 did not complete study 
4--- wi1hdrew consent 
,, �' 
1 1  completed 1 st phase and crossed 1 2  completed 1 st phase and crossed 
over to 2nd phase with SC over to 2nd phase with IP 
treatment treatment 
,, V 
1 1  completed the study and 12  completed the study and 
were included in analysis were included in analysis 
Flowchart. IP = intraperitoneal; SC = subcutaneous 
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60 Chapter 4 The patient characteristics are listed in Table 1. The mean age was 43.6±11.8 years, and the mean diabetes duration was 22.6±10.6 years. The mean numbers of hypoglycemic events grades 1 and 2 were 4.0±2.7 and 2.7±1.9 per week, respectively. The mean HbA1c level was 8.6±1.1%. Table 1. Baseline Characteristics Characteristic Male sex Age (years) Diabetes du ration (years) Cu rrent smoker (%) Systol ic blood pressure (mm Hg) Diasto l ic  b lood pressu re (mm Hg) Body weight (kg) BMI (kg/m2) Hypog lycemia during qua l ification phase (n/wk) 1 Grade 1 Grade 2 Time spent in g lucose range (%) 2 Hypogylcemia Eug lycemia Hyperg lycemia HbA1c (%) Previous mode of insu l in  therapy CSU MDI Insu l i n  dose during qua l ification phase (IU/day) All (n = 24) 11 (46) 43.6 ± 11.8 22.6 ± 10.6 5 (21) 138.5 ± 21.8 80.1 ± 7.8 81.5 ± 15.7 26.4 ± 4.7 4.0 ± 2.7 2.7 ± 1.9 8.1 ± 7.7 45.2 ± 12.6 46.7 ± 18.0 8.6 ± 1 .1 20 (83) 4 (9) 46.3 (35 .5 ,  70.2) Treatment mode in 1st phase CIPII SC insulin (n= 12) (n= 12) 6 (50) 5 (42) 43.3 ± 11.9 43.9 ± 12.2 20.6 ± 9.5 24.7 ± 11.6 2 (17) 3 (25) 141.5 ± 20.2 135.5 ± 23.7 82.7 ± 6.5 77.6 ± 8.4 81.3 ± 18.0 81.8 ± 13.9 26.3 ± 5.3 26.4 ± 4.3 4.1 ± 2.9 3.8 ± 2.7 2.8 ± 1.8 2.6 ± 2.0 7.2 ± 6.9 9.0 ± 8.6 44.2 ± 10.6 46.1 ± 14.8 48.6 ± 15.2 44.9 ± 20.9 8.5 ± 1.0 8.6 ± 1.2 11 (92) 9 (75) 1 (8) 3 (25) 44.1 (35.8, 80.0) 47.0 (35.1, 56.2) Data a re n (%) or  mean ± SD or med ian  (interquarti le range) .  CIPII = continuous i ntra peritoneal insu l in i nfusion; SC = subcutaneous; BMI = body mass i ndex; CSU = conti nuous subcutaneous i nsu l in  i nfusion; M DI = mu lti p le da i ly i njections. 1 Hypog lycemia grade 1 is defined as blood g lucose va lue < 4.0 mmol/L, hypog lycemia g rade 2 is defined as blood g lucose va lue < 3.5 mmol/L. 2 Time spent in hypog lycemia is defined as percentage of continuous g lucose mon itor ing (CGM) recordings of <4.0 mmol/L, time spent in eug lycemia is defined as percentage of CGM record ings between 4.0-10.0 mmol/L and time spent in hyperg lycemia is defined as percentage of CGM recordings > 10.0 mmol/L. 
Glycemic control with CIPII - prospective study 
One patient withdrew consent during the first treatment phase while on CIPII 
because of admission to a psychiatric hospital due to a depressive disorder. The 
patient chose to continue CIPII treatment after withdrawal from the trial, as did all 
the patients who completed the study. 
Outcome 
Hypoglycemia 
The rate of hypoglycemia grade 1 with CIPII was 3.5±2.3 per week compared to 
4.0±2.6 per week during SC insulin treatment (mean difference: -0.50 (95%CI:-
1.16,0.l 7)) (Table 2). 
The rate of hypoglycemia grade 2 was 2.3± 1.7 per week with CIPII compared to 
2.7± 1.9 per week during SC insulin treatment (mean difference: -0.43 (95%CI:-
0.89,0.04)). 
Two episodes of hypoglycemia grade 3 occurred during CIPII treatment and five 
episodes during SC treatment (all in a single patient). 
Glycemic control 
HbA1c decreased with CIPII from 8.6±1.1% to 7.5±0.7% after 3 months and 
remained stable at 6 months (7.5 ±0.9%). During SC treatment there was no change 
in glycemic control (Figure 3). When taking the effect of the treatment order into 
account, HbA1c improved -0.76% (95%CI:-1.41,-0.11) with CIPII compared to SC 
insulin treatment (absolute values; Table 2). The effect of treatment order was 0.37 
(95%CI:-0.28,1.02) after 6 months. 
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baseline 0 3 6 
Months 
Mean HbA1c (%) at basel ine and during subcutaneous (SC) insu l in  therapy (grey l i nes) and 
intraperitonea l i nsu l i n  (IP) therapy (black l ines). * p <0.05 between therapy groups (so l id 
l i nes). Dashed l ines indicate HbA1c i n  the 2 treatment order g roups; smal lest dashes indicate 
SC insul in first, CIPII second g roup; larger dashes indicate CIPII first, SC insu l in second. The I 
bars represent standard errors. 
Glucose profile (CGM recording) 
The time spent in hypoglycemia was not significantly different between CIPII and 
SC treatment (-2.0% (95%CI:-5.4,1.3)). However, the time spent in euglycemia was 
10.9% more with CIPII compared to SC treatment (95%CI:4.6,17.3). Subjects spent -
8.9% (95%CI:-16.7,-1.1) time in hyperglycemia with CIPII compared to SC insulin 
treatment (Table 2, Figure 4). 
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Mean (SE) t ime spent in hypog lycemic range ( <4.0 mmol/L; panel A), eug lycemic range (4.0-
10.0 mmol/L; panel B) and hyperg lycemic range (> 10.0 mmol/L; panel C) at basel ine (g rey 
bars) and during subcutaneous insu l in  therapy (wh ite bars) and intraperitoneal insu l i n  
therapy (black bars). * p <0.05 between therapy g roups. 
Insulin usage and clinical parameters 
There were no sign ificant d ifferences between CIPII and SC i nsu l i n  treatment with 




Table 2. Change per treatment mode and overa l l  CIPII treatment effect 
Characteristic Treatment mode Treatment Effect 
CIPII SC insulin adjusted for treatment 
HbA1c (%) 
Hypog lycemia grade 1 (n/wk) 2•3 
Hypog lycemia grade 2 (n/wk) 2•3 




Insu l in  dose (IU/day) 2 
Systol ic  b lood pressure (mm Hg) 2 
BMI ( kg/m2) 2 
(n =23) 
Change 
-0.73 ± 1.25 
-0.64 ± 2.11 




0.5 (-6.8, 5 .0) 
0.4 ± 17.6 
-0.4 ± 1.2 
(n =23) order 1 
Change mean d ifference 
(95% CI) 
0.05 ± 0.54 -0.76 (-1.41, -0.11) 
-0.15 ± 1.33 -0.50 (-1.16, 0.17) 
-0.07 ± 1.07 -0.43 (-0.89, 0.04) 
-1.3 ±8.3 -2 .0 (-5.4, 1.3) 
-4.1± 17.2 10.9 (4.6, 17.3) 
5 .4± 19.5 -8.9 (-16.7, - 1.2) 
0.3 (-6.7, 5 .8) 
-4.0 ± 16.3 3.0 (-2 .6, 8.7) 
0.2 ± 0.9 -0.4 (-0.9, 0.2) 
Data for change are mean ± SD or median (interquarti le range). CIPII = continuous 












1 Mean d ifferences with 95% CI adjusted for treatment order a re calcu lated using the H i l ls­
Armitage method .[14] 2 Change from basel ine is reported. 3 Hypog lycemia grade 1 is defined 
as blood g lucose va lue < 4.0 mmol/L, hypog lycemia grade 2 is defined as b lood g l ucose 
va lue < 3.5 mmol/L. 4 Time spent in hypog lycemia is defined as percentage of continuous 
g lucose monitoring (CGM) record ings of <4.0 mmol/L, time spent in eug lycemia is defined 
as percentage of CGM recordings between 4.0-10.0 mmol/L and time spent in 
hyperg lycemia is defined as percentage of CGM recordings > 10.0 mmol/L. 
Adverse events and device complications 
There were no incidences of i ntraperitoneal pump or catheter ma lfunction.  One 
subject developed a postoperative pump pocket hematoma requ i ring surg ica l 
d ra inage, but neither insu l i n  de l ivery nor its action was affected. In 3 subjects, 
pro longed pa in  occurred, which was successfu l ly treated with ora l  ana lges ics (n = 2) 
and relocation of the catheter (n = l) .  
During the crossover phase, after receiving SC insu l i n, 1 patient was d iag nosed with 
myocard ia l  ischemia and subsequently treated with coronary artery bypass g raft ing.  
After an  extension of the crossover phase, this subject continued with the tria l .  
Conclusions 
With CIPII there was no s ignificant decrease in the number of hypog lycemic events. 
Nevertheless, treatment with CIPII did reduce H bA1c l evels by 0.76% compared to 
--------
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SC insulin (absolute value). The improvement in HbA1c was accompanied by an 
increased time spent in euglycemia and less time spent in hyperglycemia, both 
without any increase in either daily insulin dose or BMI. At the end of the study, all 
patients opted to continue with CIPII. 
Haardt et al. performed a randomized study comparing CIPII in a crossover manner 
with SC human insulin by MDI in 9 patients with type 1 diabetes.[16] . They reported 
a 1.3% difference in HbA1c levels after 6 months in favor of CIPII as well as a 
reduction in glucose variability and hypoglycemic episodes when treating with CIPII 
(16). The only other randomized controlled trial comparing CIPII with SC insulin in 
patients with type 1 diabetes (n=21) had a parallel design, and found no difference 
in HbA1c levels.[17] Since these two studies were published, insulin analogues with 
more physiological profiles have become widely available, and when used in CSII 
improve glycemic control.[18-23] No randomized trial comparing regimens based 
on insulin analogues with CIPII has been previously published. A 45-day 
retrospective open label trial in 14 patients with type 1 diabetes compared CIPII 
with CSII using insulin Lispro, and reported a 0.5% lower average HbA1c with 
CIPII.[24] 
One major limitation is that due to budget constraints, we were only able to include 
24 patients in our study, instead of the projected 40, which severely reduced the 
statistical power. Furthermore, four patients used MDI instead of CSII in the control 
phase which may have affected the results. Another possible source of bias that we 
tried to minimize by using a crossover design is the influence of subject 
preferences and expectations. 
Taking recent price increases into account, it is not likely that this treatment option 
will be cost effective in the near future, although a formal cost benefit analysis has 
not been done. 
Based on our results, we recommend considering CIPII as a treatment option for 
those patients with type 1 diabetes who fail to reach satisfactory glycemic control 
on other intensive insulin treatment regimens. 
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Continuous intraperitoneal insulin infusion (CIPII) with an implantable pump is an 
alternative treatment option next to subcutaneous (SC) insulin therapy in type 1 
diabetes. Our aim was to investigate the effects of CIPII compared to SC insulin on 
health related quality of life (HRQOL) and treatment satisfaction, and to perform a 
cost analysis. 
Research Design and Methods 
In an open-label, prospective, crossover, randomized, 16-month study, the effects 
of CIPII and SC insulin were compared in 24 patients. Outcome measures were 
HRQOL as assessed with questionnaires (Short Form health survey (SF-36) and 
WHO-wellbeing index (WHO-5)). Patient satisfaction was assessed with the 
Diabetes Treatment Satisfaction Questionnaire (DTSQ). Direct costs of CIPII were 
calculated and compared to direct costs of continuous subcutaneous insulin 
infusion (CSII). 
Results 
Scores were significantly higher on the all except two of the SF-36 subscales, and 
the component summaries with CIPII compared to SC therapy. Final WHO-5 score 
with CIPII was 64.9 (22.7) compared to 45.2 (22.7) with SC treatment (p<0.01). Mean 
difference in DTSQ score at the end of treatment was 9.3 (4.8, 13.9), favouring CIPII. 
Direct pump- and procedures associated costs for implantable pump therapy were 
estimated at €30,901 in the first year and €7,579 for the following 6 years, 
translating into a yearly cost estimate of €10,910 compared to a €4,810 yearly cost 
estimate for CSII. 
Conclusions 
Apart from improving glycemic control, CIPII with implantable pumps improved 
HRQOL and treatment satisfaction as compared to SC insulin. Direct pump- and 
procedures associated costs are considerably higher, however. 
Quality of life, treatment satisfaction and costs with CIPII - prospective study 
Introduction 
Subcutaneous (SC) therapy does not result in an acceptable and stable long-term 
glycemic control in a subset of patients with type 1 diabetes, despite all the 
efforts.[1] Insulin delivered through the intraperitoneal (IP) route can be an 
alternative for this patient category.[2] We recently showed that treatment with 
continuous intraperitoneal insulin infusion (CIPII) results in better glycemic control, 
expressed as a 0.8%-point decrease in HbAlc.[3] Apart from assessing glycemic 
control, it is also important to assess what the influence of this form of therapy is 
on health related quality of life (HRQOL) and treatment satisfaction. Besides 
providing a different route for insulin administration, a surgical procedure is 
needed to insert the pump for CIPII in the subcutaneous layer of the abdominal 
wall. Furthermore, the pump insulin reservoir has to be refilled during an outpatient 
clinic session transcutaneously about every 3 months. With continuous 
subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) on the other 
hand, infusion sets have to be replaced by the patient every 2 to 3 days, and 
subcutaneous injections have to be administered at least 4 times daily, respectively. 
Above stated procedures can all have their impact on HRQOL and treatment 
satisfaction. 
Furthermore, there are no up-to-date data regarding costs of CIPII. The costs of 
insulin and pumps have changed considerably during the last few years. Therefore, 
the aim of this study was to assess the effects of CIPII on HRQOL and treatment 
satisfaction compared to intensified SC insulin therapy, and to provide up-to-date 
cost calculations, concentrating on direct pump- and procedures associated costs. 
Research design and methods 
This investigator initiated study had a crossover, randomized design and was 
conducted in a single centre in The Netherlands (lsala Clinics, Zwolle). The design 
and the metabolic outcomes have been described in detail previously.[3] Briefly 
regarding the design, adult subjects with type 1 diabetes, inadequately controlled 
with MDI or CSII, were randomized to receive either 6 months SC insulin therapy 
followed by 6 months CIPII, or to receive both treatments in opposite order. A 3-
month qualification phase in an attempt to optimize glycemic control with patients' 
pre-study mode of therapy was instituted before randomization. Inclusion and 
exclusion criteria are listed in Table 1. 
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Table 1. Inclusion and exclusion criteria 
Inclusion criteria --------------------------
Type 1 diabetes 
HbA1c � 7.5% and/or � 5 hypog lycemic events per week 
1 
Fasting c-peptide < 0.20 nmol/L 
Age 18-70 years 
Currently treated with MDI /  CSII -----------------------
Exclusion criteria 
Impaired renal function: plasma creatin ine � 150 µmol/L / eGFR s 50 ml/min 
Cardiac problems: unstable ang ina pectoris / myocardia l  infarction within previous 12 
months / NYHA class III-IV 
a l lergy for insu l in  (known / suspected) 
Menta l retardation 
Treatment for sch izophrenia / organ ic menta l d isorder / bipolar d isorder (current / past) 
Severe untreated prol iferative retinopathy 
H istory of cancer, exc luding wel l -d ifferentiated thyroid carc inoma, breast carcinoma without 
lymph node metastases and skin carcinoma 
Current use of ora l  corticosteroids / suffering from cond ition  which necessitated 
ora l/systemic corticosteroid use more than once in previous 12 months 
Substance abuse, other than n icotine 
Insufficient knowledge of the Dutch l anguage to understand study requ i rements 
Participation in tria ls involving investigational products with in 30 days prior to tria l entry 
Plans to engage in activities which requ i res going 25 feet below sea level 
Any condition the investigators feel wou ld interfere with tria l  partic ..... ip_a_ti_o_n ______ _ 1 hypog lycemic event is defi ned as measured blood g lucose va lue < 4.0 mmol/L. 
MDI = mu ltip le dai ly injections; CSII = continuous subcutaneous insu l i n  i nfusion; eGFR = 
estimated G lomeru lar Fi ltration Rate; NYHA = New York Heart Association. 
Insulin (U400 semi synthetic human insulin of porcine origin; Hoechst, Frankfurt, 
Germany, recently Sanofi-Aventis) was administered with an implanted pump (MIP 
2007C, Medtronic/Minimed, Northridge, CA, USA). The pump was implanted under 
general anaesthesia at the start of the CIPII phase in all subjects. The IP pump of 
subjects who received SC insulin in the 2nd treatment phase was filled with an inert 
fluid at the end of the 1st treatment phase. The procedure of pump implantation in 
our clinic and in all study participants is described in detail elsewhere.[4] SC insulin 
was delivered with either MDI or CSU, whatever the patient used prior to the study. 
Twice per month, the study subjects were in contact with a diabetes specialist 
nurse, alternating telephone and clinic visits. 
The study was performed in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from all patients, and the protocol was approved 
by the Medical Ethics committee of the Isa la Clinics. 
Quality of life, treatment satisfaction and costs with CIPU - prospective study 
Health related quality of life and treatment satisfaction measurement 
For HRQOL assessment, the 36-item Short-Form Health Survey (SF-36) and the 
World Health Organization-Five Well-Being Index (WHO-5) were used. The SF-36 is 
a widely used, self-administered generic questionnaire with 36 items involving 8 
subscales: 'physical functioning', 'role limitations due to physical problems', 'bodily 
pain', 'general health perception', 'vitality', 'social functioning', 'role limitations due 
to emotional problems', and 'mental health'. Scale scores range from O to 100, with 
higher scores indicating better HRQOL.[5] In addition, a physical and mental 
component summary (PCS and MCS, respectively) score can be determined.[6] 
The WHO-5 is designed to measure positive well-being and is reported to be better 
in identifying depression than the MCS of the SF-36.[7,8] It consists of 5 items with 
a raw total score ranging from O to 25, which can be transformed to a O to 100 
scale. A score below 50 suggests poor emotional well-being.[9] 
Treatment satisfaction was measured with the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ). All 8 items are scored on a 7-point scale. Two items assess 
perceived frequency of hyperglycemia and hypoglycemia (scale: 0 to 6), with lower 
scores indicating less hyper- and hypoglycemia, respectively; 6 items comprise the 
treatment satisfaction scale.[10] The scale score ranges from O to 36, with higher 
scores indicating higher satisfaction. 
Costs 
Cost calculations were done using the Dutch manual for costing as a guideline and 
performed from a health care payers perspective.[11] Costs for CIPU and CSU were 
calculated using 2007 local protocols and prices. No comparison with costs for MDI 
was made. For CSU treatment prices were used for the most frequently used pump 
and its accessories in our hospital region; the Paradigm 512/712 
(Medtronic/Minimed, Northridge, CA, USA). Usage of medical consumables like 
insulin infusion sets and reservoirs was based on guidelines.[12] Drug costs for CSU 
were based on the Dutch national drug compendium (June 2007 prices; € 6.33* per 
3 ml vial Insulin Aspart or Lispro 100 IU/ml), increased with the pharmacists' fee (€ 
6.10) on the assumption of 4 prescriptions issued each year, and increased with 6% 
VAT. [*personal communication from the Drug Information System of the Health 
Care Insurance Board][l3] Average daily insulin dose was based on trial data. For 
CIPII treatment actual prices for both the IP pump and the IP insulin were used. 
Since the CIPII trial period lasted 6 months, rates for rinse and refill procedures 
were based on the 2007 protocol and historical data instead of trial data (1.33  and 
4.68 times per year, respectively). This choice was made because of the duration of 
the study. Trial based cost would underestimate the real costs, as for example 
patients will not receive a standard rinse procedure during, but on average three 
months after the study. Life spans of 4 and 7 years were assumed for SC and CIPII 
pumps, respectively.[14,4] Costs for self monitoring of blood glucose and 
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outpatient visits to health care providers were considered to be equal for both 
therapy strategies and therefore left out of calculations. 
Statistical analysis 
Descriptive summaries included mean (± standard deviation (SD)) for normal 
distributed variables and median with interquartile range (IQR) for other variables. 
Normality was examined with Q-Q plots. A significance level of 0.05 (2-sided) was 
used. The general linear model was used to test differences, taking treatment order 
into account. To calculate mean differences with 95% confidence intervals (95%CI) 
for outcomes the Hills-Armitage approach was used.[15] McNemar's test was used 
to compare paired proportions. Statistical analyses were performed with SPSS 
software, version 15.0 and 16.0. 
Results 
Patients 
Figure 1 is the study flow chart; 25 patients entered the study between June 2006 
and December 2007. Demographic and clin ical baseline characteristics of the 
patients are listed in Table 2. Mean baseline HbAlc and frequency of hypoglycemia 
is relatively high. HRQOL and treatment satisfaction parameters at baseline are also 
presented in Table 2. On average, the patients had a poor emotional well-being at 
the start of the study. 
One patient withdrew from the study during the first treatment phase while treated 
with CIPII. The reason for withdrawal was not related to the study. The patient 
chose to continue CIPII after withdrawal from the trial. 
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Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flowchart 
I 50 patients were assessed for eligibility I 
24 did  not meet entry criteria 1 4  refused to participate 10 did not meet inclusion criteria 
_____. 4 had good glycemic control 2 were trying to conceive 1 had ps)Chiatric illness 3 had other exclusion criteria 
� 
1 did not enter qualification phase due to unavailability of IP-pump 
,, 
I 25 entered qualification phase I 1 was excluded --. - reached acceptable glycemic control at the end of qualification 
,, 
24 were randomized I 
• • 
1 2  allocated to receive IP 12  allocated to receive SC 
treatment in 1 st phase treatment in 1 st phase 1 did not complete study 
� - withdrew consent 
... , , 
1 1  completed 1 st phase and crossed 1 2 completed 1 st phase and crossed 
over to 2nd phase with SC over to 2nd phase with IP 
treatment treatment 
,, , , 
1 1  completed the study and 12 completed the study and 
were included in analysis were included in analysis 
Flowchart. IP = intraperitoneal; SC = subcutaneous 
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Diabetes duration (years) 
Current smoker 
Systolic blood pressure (mm Hg) 
BMI (kg/m2) 
HbAlc (%) 













SF-36 summary scores 
Physical Component Summary 





43.6 ± 11.8 
22.6 ± 10.6 
5 (21) 
138.5 ± 21.8 
26.4 ± 4.7 
8.6 ± 1.1 
4.0 ± 2.7 
2.7 ± 1.9 
71.7 ± 21.8 
60.9 ± 24.5 
25 (0, 75) 
100 (0, 100) 
66.7 ± 22.3 
44.2 ± 21.7 
58.2 ± 25.3 
38.9 ± 17.5 
38.5 ± 9.8 
44.7 ± 13.2 
45.2 ± 23.7 
Total score 23.7 ± 7.0 
Perceived hypoglycemia score 3.2 ± 1.9 
Perceived hyperglycemia score 5.0 ± 1.1 
Data are n (%) or mean ± SD or median (interquartile range). 1 Hypoglycemia grade 1 is 
defined as blood glucose value < 4.0 mmol/L, hypoglycemia grade 2 is defined as blood 
glucose value < 3.5 mmol/L. HRQOL = health related quality of life; SF-36 = 36-item Short­
Form Health Survey; WHO-5 = World Health Organization-Five Well-Being Index; DTSQ = 
Diabetes Treatment Satisfaction Questionnaire 
HROOL 
Scores on most subscales of the SF-36 improved significantly with CIPII compared 
to baseline. Improvements ranged from 4 to 56%. Largest improvements were seen 
on subscales 'role limitations due to physical limitations', 'role limitations due to 
emotional limitations' and 'vitality'. With SC treatment, mean score of the subscale 
'physical functioning' decreased, other scores did not change significantly. When 
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endpoint scores for CIPII and SC treatment were compared, the scores on all 
subscales and summary scores were significantly higher with CIPII as compared to 
SC treatment, with the exception of 'social functioning' and 'bodily pain' (see table 
3). 
Table 3. Health related quality of life and treatment satisfaction outcome 
Treatment mode Treatment effect 
Characteristic CIPII SC insul in adjusted for p 
(n=23) (n=23) treatment 
order 1 
SF-36 subscales 
Physica l function ing 
End of treatment phase 76.7 ± 22.2 64.1 ± 24.4 12.7 (4.8, 20.5) < 0.01 
Change from basel ine (%) + 6.0 -11.42 
Social function ing 
End of treatment phase 72.8 ± 27.3 60.3 ± 28.9 12.5 (-0.7, 25.6) 0.06 
Change from base l ine (%) + 15.5 -4.3 
Role l imitations-physical 
End of treatment phase 60.9 ± 41.9 35.9 ± 43.8 25.1 (8.0, 42.1) < 0.01 
75 (25, 100) 0 (0, 100) 
Change from basel i ne  (%) + 55.62 -8.3 
Role l imitations-emotional  
End of treatment phase 82.6 ± 36.1 65.2 ± 42.0 17.6 (3.6, 31.5) 0.02 
100 (100, 100) 100 (33.3, 100) 
Change from basel ine (%) + 23.92 -2.2 
Menta l health 
End of treatment phase 75.0 ± 17.9 65.0 ± 20.8 9.9 (3.3, 16.6) < 0.01 
Change from basel ine (%) + 10.82 -3.9 
Vita l ity 
End of treatment phase 58.0 ± 20.8 39.1 ± 21.1 19.1 (9.8, 28.3) < 0.01 
Change from base l ine (%) + 29.62 -12.6 
Bodi ly pai n  
End  of  treatment phase 61.3 ± 24.4 57.3 ± 31.6 3.8 (-7.9, 15.5) 0.50 
Change from base l ine (%) + 3.9 -2.9 
Genera l  health 
End of treatment phase 53.2 ± 18.1 42.2 ± 20.7 11.1 (3.1, 19.1) < 0.01 
Change from base l ine (%) + 34.12 +6.2 
Data a re mean ± SD, percentage mean change from basel ine or median (interquarti le range) . 
1Data for treatment effect are mean d ifferences (95% CI) adjusted for treatment order 
calcu lated us ing the H i l l s-Armitage method. [15] 2 p<0.05 for change from baseline. CIPII = 
continuous i ntraperitonea l  insu l in i nfusion; SC = subcutaneous; SF-36 = 36- item Short-Form 
Hea lth Survey 
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Table 3 (continued). Health related quality of life and treatment satisfaction 
outcome 
Characteristic 
SF-36 summary scores 
Treatment mode 
CIPII SC insulin 
(n=23) (n=23) 
Treatment effect 




Physic a I Component Summary 
End of treatment phase 
Change from basel ine (%) 
Mental Component Summary 
End of treatment phase 
Change from basel ine (%) 
WH0-5 score 
End of treatment phase 
42.1 ± 10.3 
+ 8.7 
50.8 ± 11.7 
+ 11.72 
64.87 ± 22.69 
37.3 ± 12.4 4.8 (0.8, 8.9) 0.02 
-3.8 
44.7 ± 12.2 6.2 (2.1, 10.3) <0.01 
-1.9 
45.2 ± 22.7 19.8 (9.9, 29.6) <0.01 
Change from baseli_ne-----'-(o/c""""'o) ______________________ _ + 41.3
2 -1 .5 
DTSQ 
Total score 
End of treatment phase 
Change from basel ine (%) 
Perceived hypog lycemia score 
End of treatment phase 
Change from basel ine (%) 
Perceived hyperg lycemia score 
End of treatment phase 
Change from basel ine (%) 
32.6 ± 3.9 
+ 37.22 
2.4 ± 1.6 
- 25.3 
2.6 ± 1.6 
- 47.82 
23.3 ± 9.2 9.3 (4.8, 13.9) <0.01 
-1.6 
3.7 ± 2.2 - 1.3 (-2.3, -0.3) 0.01 
+ 13.3 
4.8 ± 1.3 -2 .2 (-3 .0, -1.5) <0.01 
-3 .5 
Data a re mean ± SD, percentage mean change from basel ine or median ( interquarti le range) . 
1Data for treatment effect a re mean d ifferences (95% CI) adjusted for treatment order 
calcu lated using the H i l ls-Armitage method. [15] 2 p<0.05 for change from basel ine. CIPII = 
continuous intraperitoneal insu l in i nfusion; SC = subcutaneous; SF-36 = 36-item Short-Form 
Health Survey; WHO-5 = World Hea lth Organization-Five Wel l -Being Index; DTSQ = 
_f 78 
Diabetes Treatment Satisfaction Questionnaire 
The mean difference (95% CI) on the WHO-5 between CIPII and SC treatment was 
19.8 (9.9, 29.6) points. With CIPII treatment, the number of patients scoring below 
50 was half of that with SC treatment (p=0.02; see figure 2). 
Quality of life, treatment satisfaction and costs with CIPII - prospective study 




1 0  
■WHO score < 50 
□WHO score � 50 p = 0.01 6 
------------------------------- ----------+-------------------------1------------
0 -+-_ __., ___ .,__ ____ ___. ___ ...,___ ___________ ----i 
baseline IP insulin SC insulin 
Number of patients with WHO-5 score below 50, suggesting poor wel l -being. IP = 
intraperitoneal; SC = subcutaneous 
Treatment satisfaction 
Mean overall DTSQ score increased 37% with CIPII from a baseline score of 24 
points. Mean difference to SC treatment was 9.3 (4.8, 13.9) points at the end of 
treatment. Furthermore, with CIPII, subjects perceived significantly less 
hypoglycemic and hyperglycemic events than with SC treatment. 
Costs 
Costs for CIPII and CSII are stated in table 4. Direct pump- and procedures related 
costs for treatment with CIPII were much higher than direct costs for CSII, mainly 
because of the high costs of the IP pump (€ 20,000 at the time of the study). 
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Table 4. Di rect pu mp- and proced ures associated costs of CIPII and CSII 
CIPII Unit Units per Total costs 1 
costs (€) procedure (€) 
Implantation procedure (/7 yrs) 
Pump 20,000 1 20,000 
Insulin (10 ml/vial) 400 4 1,600 
Diluent (vial) 12 1 12 
Other materials 210 
Hospital stay (day) 200 2 400 
Staff expenses 2 1,100 
Subtotal € 23,322 
Refil l  procedure (4.68 times per yr) 
Insulin (vial) 400 2 800 
Diluent (vial) 12 1 12 
Other materials 60 
_2!aff expenses 150 
Subtotal € 1,022 
Rinse procedure (1.33 times per yr) 
Insulin (vial) 400 4 1,600 
Diluent (vial) 12 1 12 
Other materials 330 
Staff expenses 160 
Subtotal € 2,102 
Implantation procedure costs year 1 23,322 23,322 
Refill procedure costs per year 4.68 times 1,022 4,783 
Rinse procedure costs per year 1.33 times 2,102 2,796 
Total costs year 1: € 30,901 
Annual costs year 2 - 7: € 7,579 
Average annual costs CIPII: € 10,910 
CSII 
Pump € 3,535 € 3,747 
Insulin3 € 6.33 61 € 435 
Infusion set € 19.97 146 € 3,091 
Reservoir € 4.60 61 € 297 
Other materials € 50 
Total costs year 1: € 7,620 
Annual costs year 2 - 4: € 3,873 
Average annual costs CSII: € 4,810 
1 including VAT. 2 including O.R., excl. overhead. 3 including pharmacists fee. CIPII = 
continuous intraperitoneal insulin infusion; CSII = continuous subcutaneous insulin infusion 
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Conclusions 
Treatment with CIPII improved HRQOL and treatment satisfaction considerably in 
patients with type 1 diabetes who failed to reach satisfactory metabolic control with 
MDI and CSII, albeit against currently high costs. 
Our results expand previously published data regarding HRQOL with CIPII. Saudek 
et al. reported improved aspects of quality of life with IP therapy as compared to 
MDI in type 2 diabetes mel litus.(16] Selam et al. found no effect on HRQOL but 
improved patient satisfaction in type 1 diabetes patients in their non-randomized 
study.(17] In a cross-sectional study, Renard et al. reported higher satisfaction with 
IP pumps compared to insulin injections and a lower diabetes worry score.[18] 
Striking improvement of vitality and mental health on the SF-36 and a decline of 
problems in work and daily activities due to emotional problems indicate that CIPII, 
apart from physical improvement, improves mental components of health status as 
wel l , which was confirmed by the results of the WHO-5 questionnaire. It is 
reassuring to find CIPII treatment satisfaction being high and increased compared 
to SC treatment together with the beneficial effects of CIPII on HRQOL. The 
initiation of CIPII necessitates hospital admission and a surgical procedure to insert 
the pump and the catheter intra-abdominal ly, and could therefore be expected to 
have negative effects compared to treatment modalities not needing surgery. The 
improvement in glycemic control with less perceived complaints of hypo- and 
hyperglycemia probably compensates for this potential negative effect, and as 
opposed to the daily hassle associated with SC treatment, we found that CIPII 
improves HRQOL and treatment satisfaction. 
Annual costs of CIPII are about € 6,000 higher than the annual costs of CSII at the 
moment, mainly because of the high price of the imp lantable pump and the insulin 
used in IP pumps. The only cost analysis with CIPII up to now was done by Haardt 
et al. in 1993.(19] They reported that, compared to multip le subcutaneous 
injections direct costs of CIPII were 2.6 fold higher at that time, even with insulin 
provided free of charge. A formal cost-effectiveness analysis was beyond the scope 
of this study. Future analyses wil l probably turn out to be even more in disfavour of 
CIPII regarding the costs aspect, because recently, the price for implantable pumps 
has risen considerably. 
Big steps regarding improvement of glycemic control have been made in the past 
with the availability of insulin analogues and continuous subcutaneous pumps.(20] 
Insulin analogues with more physiological profiles have become widely available, 
and when used in CSII improve glycemic control .(21-23] Many patients are able  to 
achieve target levels with these treatment modes combined with adequate self 
care. Stil l ,  a considerable proportion of type 1 diabetes patients remains, that is not 
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able to reach adequate control and satisfactory HRQOL despite all efforts. It is our 
opinion that, when choosing a treatment modality together with the patient, a wide 
range of parameters, including HbA1c, HRQOL and treatment satisfaction will have 
to be taken into account. 
Our study has its limitations. We planned to enroll 40 patients in our crossover trial; 
however, we were only able to include 24 patients, because of the considerable 
increase in costs and scarcity of supplies during the study. 
In conclusion, based on our results, we conclude that CIPII has clear beneficial 
effects on health related quality of life and satisfaction with treatment in selected 
patients with type 1 diabetes. CIPII should be (re)considered as a treatment option, 
at least when satisfactory results of treatment are not reached with subcutaneous 
intensive insulin treatment regimens. 
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In diabetes, strict glycemic control reduces risk of complications. One mode of 
therapy is continuous intraperitoneal insulin infusion (CIPII). With CIPII, like all 
intensified treatment strategies, frequent assessment of glucose levels is 
mandatory. Real-time (RT)-continuous glucose monitoring (CGM) gives RT 
information without the need for multiple invasive measurements. In theory, CIPII 
combined with RT-CGM could provide near normal glucose profiles. The objective 
of this study is to investigate effectiveness and safety of RT-CGM in patients treated 
with intraperitoneal insulin through an implanted pump. 
Methods 
In an open-label, crossover, randomized study, effects of 6-day open RT-CGM use 
were studied in 12 type 1 diabetes patients on CIPII, with blinded RT-CGM used as 
a control. Primary outcome was time in euglycemia. Secondary outcomes included 
time in other glucose ranges, incidence of adverse events, and patient satisfaction. 
Agreement of self-measurement of blood glucose (SMBG) and RT-CGM 
measurements was assessed. 
Results 
Median time spent in euglycemia was 68.2% (55.9-72.3%) with open RT-CGM and 
64.9% (55.3-71.2%) with blinded RT-CGM (P = 0.25). Time spent in other glucose 
ranges did not differ (P > 0.05). There were no serious adverse events. Patient 
satisfaction was good. Median relative absolute difference of SMBG and RT-CGM 
values was 13.9%. Bland-Altman analysis showed a mean difference of -0.31 mg/dl 
with lower and upper limits of agreement of -77.0 and + 76.4 mg/dl, respectively. 
Conclusion 
Short-term use of RT-CGM, although safe and with good patient satisfaction, does 
not result in more time spent in euglycemia, nor does it change time spent in other 
glucose ranges in our population of type 1 diabetes patients receiving CIPII. 
Real-time continuous glucose monitoring with CIPII 
Introduction 
Strict glycemic control reduces the risk of complications in diabetes mellitus.[1,2] 
To reach such control in type 1 diabetes mellitus, current treatment options are 
multiple daily injections (MDI), continuous subcutaneous insulin infusion (CSII), and 
continuous intraperitoneal insulin infusion (CIPII) using an implanted insulin pump. 
CIPII is mainly used in patients who, despite intensive subcutaneous insulin therapy, 
do not reach acceptable glycemic control and/or have frequent hypoglycemic 
episodes (especially when accompanied by hypoglycemia unawareness) and/or 
have subcutaneous insulin resistance.[3] At the moment CIPII is only available in a 
few European countries, mostly in France, Sweden, and The Netherlands.[4,5] 
All patients on insulin treatment, regardless the mode of administration, are 
instructed to perform self-measurement of blood glucose (SMBG) multiple times a 
day to evaluate insulin treatment and to obtain information about how to adjust 
their insulin regimen.[6] SMBG is also advised when hypoglycemia or 
hyperglycemia is suspected. Still, intermittently performed blood glucose 
measurements can give only limited information on 24-h blood glucose profiles. 
Another mode of measuring glucose, using continuous glucose monitoring (CGM), 
is now available. Potential trends in glycemic profiles that would normally be 
missed with SMBG can be identified.[7,8] Real-time (RT)-CGM is a novel system that 
can provide the patient and the healthcare professional with information about the 
current glucose level without the need for multiple invasive measurements. In 
theory this would allow for near normal blood glucose profiles to be reached. RT­
CGM has proven to be effective in reducing hyperglycemic and hypoglycemic 
excursions in ambulatory patients with type 1 diabetes mellitus.[9-11] Most of 
these patients were treated with either MDI or CSII, with some receiving 
conventional insulin therapy. 
Given the indications based on which patients are treated with CIPII, RT-CGM might 
be helpful in this particular patient category. Furthermore, the combination of an 
implanted intraperitoneal insulin delivery device and a continuous (subcutaneous) 
glucose sensor could be of importance in the development of a closed loop 
system, although the subcutaneous insulin delivery device-subcutaneous glucose 
sensor and intraperitoneal insulin delivery device-intravenous glucose sensor 
combinations are currently most studied.[12,13] RT-CGM has never been tested in a 
population of outpatient type 1 diabetes mellitus patients treated with CIPII. The 
objective of this study therefore is to investigate the effectiveness and safety of RT­




Subjects and Methods 
Study population 
Subjects with type 1 diabetes mellitus with less than adequate glycemic control, 
defined as hemoglobin Ale (HbA1c) � 7.5% and/or five or more incidents of 
hypoglycemia (defined as SMBG measurement below 72 mg/dl [4.0 mmol/L]) per 
week, over 18 years of age, and treated with CIPII, were eligible for the study. 
Reasons for exclusion from the study were failure to obtain informed consent, any 
condition preventing proper handling of the device (for instands, hearing 
impairment or visual impairment), known allergy to sensor (parts), and currently 
pregnant or trying to conceive. 
The study was performed in accordance with the Declaration of Helsinki. Informed 
consent was obtained from all patients, and the protocol was approved by the 
Medical Ethics committee of the Isala Clinics (Zwolle, The Netherlands). 
Study design 
The study had a crossover, randomized design and was conducted in a single 
center (Isala Clinics) in The Netherlands. The study consisted of four periods: the 
baseline phase, the first study phase, the crossover phase, and the second study 
phase. After the baseline phase of 3 days, in which all subjects were blinded to 
sensor values, subjects were randomly allocated to one of two groups, differing in 
the order of the blinded and open mode of the RT-CGM device (Paradigm® REAL­
Time system, Medtronic MiniMed, Northridge, CA). After informed consent was 
obtained, randomization was performed using sealed opaque envelopes, which 
indicated the assigned mode of RT-CGM in the first study phase; blinded or open, 
respectively. Both study phases were 6 days in duration. A crossover phase of 1 
week was instituted between the two study phases to minimize carryover effects. 
During the crossover phase, no RT-CGM system was used. 
All patients were asked to perform SMBG (Accu-Chek® Aviva, Roche Diagnostics, 
Mannheim, Germany) at least four times daily (fasting, before meals, and before 
bedtime) and to perform SMBG seven times daily (fasting, before and after meals, 
and before bedtime) once every 3 days. 
During the study, there were six scheduled contacts with a diabetes specialist nurse 
or a study investigator: the first and the last study contact were at the diabetes 
outpatient clinic, and the others were by telephone, at the start and halfway 
through both study phases. In addition to the scheduled contacts, subjects could 
contact a diabetes specialist nurse or a study investigator throughout the study in 
case of problems or questions at any time of the day. 
During the first study visit, subjects were instructed about sensor insertion and 
calibration, after which the first sensor was inserted in the presence of the 
investigator or diabetes specialist nurse. All sensors were inserted by the subjects 
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themselves. Each sensor was worn for a maximum of 72 h. In both study phases the 
first sensor was immediately replaced by the next. Subjects kept a study diary to 
record the number of SMBG performed, the number of performed sensor 
calibrations, device alarms, and other information regarding glucose control. 
Subjects were asked to perform sensor calibration four times per day using a blood 
glucose measurement taken in a period of stable blood glucose, i.e., fasting, before 
meals, or before bedtime. 
During the open study phase, sensor alarms were set at 70 mg/dl (3.9 mmol/L) and 
200 mg/dl (11.1 mmol/L). No treatment adjustments were to be based on sensor 
values alone; all patients were instructed to use SMBG values to guide therapeutic 
decisions. Subjects were allowed to adjust insulin dose during the whole study as 
they seemed fit to do without any restrictions. 
During the last study visit, RT-CGM and SBMG data were downloaded into a 
computer, and patient satisfaction was assessed with a questionnaire. 
Primary and other outcomes 
The primary outcome measure was the percentage of time spent in euglycemia. 
Time spent in the different glucose ranges was calculated from RT-CGM data. Time 
spent in the euglycemic range was defined as percentage of CGM recordings 
between 71 and 180 mg/dl (4.0-10.0 mmol/L). 
Secondary outcome measures were percentage of time spent in hypoglycemia and 
hyperglycemia, the incidence of adverse effects, patient satisfaction, and agreement 
of paired SMBG and RT-CGM measurements. Time spent in the hypo- and 
hyperglycemic range was defined as percentage of recordings below 70 mg/dl (3.9 
mmol/L) and above 180 mg/dl (10.0 mmol/L), respectively. Patient satisfaction was 
assessed with a modifie� version of the User Acceptance Questionnaire for CGM as 
designed by Peyrot et al.[14] Next to items regarding the overall assessment of the 
device (six items), the questionnaire contains items regarding Comfort (six items), 
Sensor Operation (eight items), Sensor Use (five items), Alarms (11 items), and 
Glucose Control (seven items) on a 7-point Likert scale from 1 (strongly disagree) to 
7 (strongly agree). Furthermore, patients were asked about satisfaction with 
glucose control and whether or not they regarded their glucose control improved 
with RT-CGM. 
Demographic and clinical measurements 
At baseline, demographic and clinical parameters were recorded, including age, sex, 
and year of diagnosis of diabetes. In addition, at baseline, fear of hypoglycemia was 
assessed with the validated Hypoglycemia Fear Survey (HFS).[15,16] Aspects of 
diabetes self-care and outcome were rated, with questions regarding SMBG, 
current glucose control, and fear of hypoglycemia, on 4- or 5-point scales. 9 1  
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Sample size calculation and statistical analysis 
To test our hypothesis that use of RT-CGM can provide a 15% absolute increase in 
time spent in euglycemia with 85% power and a 5% (two-tailed), a total sample 
size of 11 was required. These calculations were based on a standard deviation (SD) 
of 14.6 as derived from a previous study in which patients receiving CIPII used 
CGM.[17] 
Descriptive summaries included mean (SD) for normal distributed variables and 
median with interquartile range for other variables. Normality was examined with 
Q-Q plots. Planned analyses were conducted to address the study objectives as 
defined, using a nominal significance level of 0.05. General linear models were used 
to test differences, taking treatment order into account.[18] If assumptions for the 
general linear models were not met, nonparametric tests were used. 
Agreement was evaluated from paired glucose values of SMBG and RT-CGM (time 
difference not more than 5 min) with median relative absolute difference (RAD) 
values and Bland-Altman analysis.[19] Statistical analyses were performed with 
SPSS (Chicago, IL) software version 16.0. All reported P values are two-sided. 
Analyses were done according to the intention to treat principle. 
Results 
Patients 
Figure 1 is the patient flow chart; 12 patients entered the study between December 
2007 and March 2008. Characteristics of the subjects are listed in Table 1. 
Table 1. Characteristics at baseline 
_C_h_a_r_a_ct_e_r_is_ti_c __________________ Of total (n= 12) 
Age (years) 43.8 (12.5) 
Ma le (n) 5 
Diabetes' duration (years) 
Time on CIPII (months) 1 
H bA1c (%) 
Time spent in g lucose range (%) 1 




Total score (range 0-112) 
Behavior subsca le (range 0-60) 
Worry subsca le (range 0-52) 2 
Data a re mean (SD) or number of subjects un less otherwise ind icated . 
24.2 (9.7) 
17.5 (10.1-53.1) 







1 Median (interquarti le range). 2 One subject (bl inded RT-CGM in first phase) left one 
question unanswered on the Behavior subsca le 
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Figure 1. Patient flow chart 
20 eligible patients received 
information regarding the study 
7 did not meet entry criteria: 
5 refused to participate 
----- 2 did not meet inclusion criteria 
1 was pregnant 
1 was currently not on CIPII 
� 
1 did not enter study due to car-
crash pri or to first study visit 
�' 
12  entered the study and were 
randomized 
! ! 
6 allocated to blinded RT-CGM in 6 allocated to open RT-CGM in 
I s t  phase I st phase 
! 
6 completed I st phase and crossed over 6 completed I st phase and cro ssed over 
to 2nd phase with open R T-CGM to 2nd phase with blinded RT-CGM 
! 
6 completed the study and were 6 completed the study and were 
included in analysis included in analysis 
Differences between groups were considerable, although not statistically significant 
because of small group sizes. Mean (SD) age was 43.8 (12.5) years. Mean (SD) 
HbA1c level was 8.5% (1.3%). Median (range) time on CIPII was 17.5 (10.1-53.1) 
years. Median (range) percentage of time spent in euglycemia during the baseline 
phase was 43.7% (31.6-75.6%). Median (range) scores on the subscales of the HFS 
were 9.0 (7.0-22.0) and 11.0 (6.3-18.3) for the Behavior and the Worry subscale, 
respectively. Other patient reported outcomes are shown in Figure 2; subjects 
mostly regarded SMBG as never or sometimes painful and regarded the number of 




Figure 2. Patient-rated response at baseline (n = 12) 
12 �
_cu_r_re_nt�g�ly_ce_m_ic_c_o_nt_ro_l -� 12  
1 0  10  
fear of da t ime hypoglycemia 
12 
fear of n i  httime hypoglycemia 
10 
0-'--�----
very poor poor moderelte good very good all of the time sometimes never all of the time sometimes 
1 0  
o....__---.-----------r--





all of the time 
1 0  
often 
very fairly 
rarely often rarely 
1 0  
o..,__,---.----
a b� not at ell fer too little too little about right often t&r too often 
Median (range) time spent in euglycemia was 68.2% (55.9-72.3%) during open RT­
CGM use compared to 64.9% (55.3-71.2%) during blinded RT-CGM use (P = 0.25). 
Secondary outcomes 
Glucose ranges 
In Figure 3 mean percentages of time spent in hyper-, hypo-, and euglycemia are 
shown for open and blinded RT-CGM use (P = 0.61 and P = 0.23 for difference in 
time spent in hypo- and hyperglycemia, respectively). More narrow glucose ranges 
are also shown; there are no significant differences in percentage of time in any of 
these glucose ranges between open and blinded RT-CGM use (P = 0.30 for 71-110 
mg/dl, P = 0.43 for 111-155 mg/dl, P = 0.34 for 156-180 mg/dl, P = 0.70 for 181-
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210 mg/dl, P = 0.20 for 211-240 mg/dl, P = 0.47 for 241-270 mg/dl, P = 0.06 for 
271-300 mg/dl, and P = 0.35 for > 300 mg/dl). 















-:;;,.70 7 1- 180 > 180 


















71-1 10 1 1 1 -155 156-180 181-210 21 1-240 241-270 271 -300 
Glucose range (mg/d l) 
Upper panel shows time in hypo-, eu-, and hyperg lycemia, respectively (P > 0.05 for a l l  
comparisons). Lower panel shows percentages of  t ime  in more narrow g lucose ranges (P  > 
0.05 for a l l  comparisons) 
Adverse events 
Patients reported no serious adverse events during either study phase. There was 
one report of redness of the skin, and two patients reported itching. There was one 
report of hematoma after sensor insertion; it was noticed only hours after sensor 
insertion, reached a maximum diameter of approximately 5-10 cm (patient report), 
and did not require further action. None of these reports required termination of 




Agreement of paired SMBG and CGM measurements 
Figure 4 shows the scatter plot of SMBG-derived glucose values versus CGM­
derived glucose values and the Bland-Altman plot. Mean difference (bias) is -0.31 
mg/dl (-0.02 mmol/L) with lower and upper limits of agreement of -77.0 and + 
76.4 mg/dl (-4.28 and +4.24 mmol/L), respectively. The scatter of the differences 
increases with increasing glucose values. Median RAD was 13.9% for all 
comparisons (n = 980). Median RAD was least for hyperglycemic values (12.4%; n = 
331), was 15.3% (n = 630) for euglycemic values, and was 25.6% for hypoglycemic 
values (n = 19). 
Figure 4. Agreement of paired CGM and SMBG measurements 
360----------------------
. . . 




I • ■  I 
� 
.. • I , ■
•
■• ■  .... : I I I 
"CJ • i: . . ( : �· · - ·, ." · : ·:• · . . "ci - · : ! . �� · ·.": .. = ·· : • ·. 
E : ,. . .. . 




•■ .. vtf ( � :•• .■ ■ •: .. •• :. ■ ■ I ■ 
. . 
a, . I • � I . . .  I .. • I I � 1so- ........................ , .. �··········;··· ··�·\········:
,
� .. ��ir]"·�t"!J..•1r••·;·'°•:-'�······'" ···········.······· · · ················ g i . . . ' '!: ·� =-:;Ii,• ·. -· : .. 
G : . L · : -
�
· ::-!: :�� · , .-:. • "": • t · 
::E 
- i • • 
• ' •
. ...,� ....... � . . • .. 
� 
• i ... . � � �� 'i,'.'':" . . �- . 
. 
f' ... i . . ·:v.- . . .. .: .· u 
. 
•, •  ···�·" . .. -:,; ,.. . . : . 













. .  . . . . 
: 
· .. � . ;i f,}.•" :■ : • I · · · 72- •...'.���i• A, 1 • 
i 






I I I I 360 
SBMG Glucose (mg/dL) 
Upper panel (p 96) shows scatter of SMBG-derived glucose values versus (GM-derived 
glucose values during the whole study (n = 980). Lower panel (p 97) shows Bland-Altman 
plot. Horizontal lines in the right panel are drawn at bias (-0.31 mg/dl) and lower and upper 
limits of agreement (-77.0 and + 76.4 mg/dl, respectively) 
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Mean of SBMG and CGM Glucose (mg/dL) 
Upper panel (p 96) shows scatter of SM BG-derived glucose values versus (GM-derived 
glucose values during the whole study (n = 980). Lower panel ( p 97) shows Bland-Altman 
plot. Horizontal lines in the right panel are drawn at bias (-0.31 mg/dl) and lower and upper 
limits of agreement (-77.0 and +76.4 mg/dl, respectively) 
Number of sensor alarms 
Mean number of sensor alarms during open RT-CGM use was 6.6 (3 .2) per day. 
Most of these were "High glucose" alarms (89.5%). Two patients turned the "High 
glucose" alarm off during part of the open RT-CGM phase; one subject turned off 
the alarm during the nights starting the third night and received 12.5 (4.0) alarms 
per day during the whole open RT-CGM phase. The other patient turned off the 
" High glucose" on the fourth day for the rest of the phase, after receiving a mean of 
9.3 alarms per day during the first half of the phase. 
Patient satisfaction and user acceptance 
Mean (SD) User Acceptance Questionnaire scores regarding Comfort, Sensor 
Operation, Alarms, Glucose Regulation, Sensor Use, and Overall Assessment (range 
0-100) were 75.0 (13.5), 67.2 (20.3), 60.6 (14.4), 52.8 (19.6), 70.8 (14.0), and 59.7 
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(20.8), respectively. Figure 5 shows patient satisfaction in more detail; mean scores 
on each item are shown. Eight out of 12 subjects rated their glucose control as 
improved with the open RT-CGM. When asked whether subjects would recommend 
use of RT-CGM to other patients with diabetes, 83% would indeed recommend it, 
although 80% of those would recommend intermittent use instead of permanent 
use of RT-CGM. 
Figure 5. User Acceptance 
� � '-----ov�era-1 1  ___. 
:J: � 
comfort sensor operation glucose control alarms sensor use 
User Acceptance Questionnaire 
Mean (standard error) scores on all items of the modified User Acceptance 
Conclusions 
Short-term use of RT-CGM does not result in more time spent in euglycemia as 
compared to blinded RT-CGM use, nor does time spent in other blood glucose 
ranges change with use of open RT-CGM in type 1 diabetes patients treated with 
intraperitoneal insulin infusion. RT-CGM proved to be safe regarding local 
complications or adverse events. 
To our knowledge, this is the first trial that investigated RT-CGM use in CIPII. RT­
CGM has been evaluated in other populations with mixed results. A recent meta­
analysis showed no effect of retrospective readings of CGM on HbA1c in children.
20 
The authors stressed that their conclusion should be interpreted with caution 
because of methodological weaknesses of the trials included. Others have found 
positive effects of short term RT-CGM use. Garg et al.[21] reported from their 
controlled study of two 3-day courses of RT-CGM use an increase in time spent in 
the target range (81-140 mg/dl [4.5-7.8 mmol/L]) from 5.52 to 6.98 h/day in 
diabetes patients receiving either CSII or MDI. This 6% absolute increase in 
percentage of time spent in euglycemia is comparable with the results of our 
current study. 
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In an earlier study with an implanted RT-CGM, time spent in the target range 
increased from 19.8% during the blinded period (mean duration, 50 days) to 37.1% 
during the following open CGM phase (mean duration, 44 days).[22] Regarding 
other outcome parameters, only Deiss et al.[23] were able to report HbA1c 
improvement in a randomized controlled study; compared to use of SMBG only, 
continuous use of RT-CGM for 3 months resulted in an 0.6% HbA1c decrease (from 
9.5% to 8.5%). 
Like us, Peyrot et al.[14] reported positive user acceptance scores of RT-CGM in 
type 1 diabetes patients just starting with CSII. 
Our results regarding device agreement are in line with previous reported accuracy 
rates of RT-CGM devices; Garg et al.[21] reported an overall median RAD for the 
STS (DexCom™ , San Diego, CA) of 15.9%. In a recently published study, Kovatchev 
et al.[24] reported a median RAD of the Guardian RT (Medtronic M ini Med) of 13.3% 
in euglycemia. A study with the Navigator® (Abbott Diabetes Care, Alameda, CA) in 
children (outpatients) provided a similar pattern of accuracy across different 
glucose ranges, with 26% for the hypoglycemic range, 10% for the hyperglycemic 
range, and 13% for the euglycemic range.[25] Our results also indicate that 
accuracy of RT-CGM falls somewhat behind that of SMBG. Optimal use of RT-CGM 
will therefore require specific education of patients and healthcare providers.[26] 
We note that in our trial only 1.9% of sensor values were in the hypoglycemic 
range, and therefore we cannot provide a definite conclusion about the 
performance of the sensor in that range. 
There are some weaknesses of this study. Our study is of limited duration and 
includes only a limited number of subjects; extended use of the RT-CGM device 
might lead to other results and would enable determination the effects on HbA1c 
and severe hypoglycemic events. The limited number of subjects has also resulted 
in slightly unequal groups at baseline, despite adequate randomization procedures. 
Second, in the open RT-CGM phase, the alarms were set at prespecified levels, and 
subjects were not encouraged to alter the settings. However, two subjects felt so 
much bothered by the "High glucose" alarm, especially during nights, that changes 
were made. One patient indicated that the frequency of alarms was a nuisance and 
that he was sufficiently informed about his glucose level by looking at the graph 
frequently. In the other patient, high glucose levels during nights were without 
direct treatment consequences and interfered with night rest. We did not give 
treatment algorithms to subjects in  this feasibility study. This  might have prevented 
adequate reaction on sensor information. However, in order to be eligible for CIPII 
in the Netherlands, patients receive extensive diabetes education, and a high level 
of diabetes self-management is mandatory. Future studies should include study 
arms with prespecified treatment algorithms. 
Although subjects were included based on objective inadequate glycemic control, 
most subjects rated their glycemic control as moderate or good and did not worry 
99 
Chapter 6 
often about hypoglycemic events. Despite the absence of an objective 
improvement in glycemic control, two-thirds of patients regarded their glucose 
control improved with the use of RT-CGM, and almost all would recommend it to 
other patients. It seems that other aspects of RT-CGM use appeal to patients. 
The questionnaire at baseline revealed a fairly positive attitude towards SMBG and 
low fear of hypoglycemia compared to a population of Dutch type 1 diabetes 
patients treated with MDI or CSII (Worry HFS score, 30.5 [12.5]).[27] The former 
might have been partly responsible for the lack of effect of RT-CGM, and the latter 
might be explained by specific aspects of intraperitoneal insulin therapy, including 
more predictable insulin profiles and better absorption.[28,29] 
We conclude that RT-CGM can be used safely in patients treated with CIPII but that 
there is no effect on glucose control, at least with short-term use. Whether long­
term use would alter this conclusion remains to be investigated. Regarding the 
ongoing development of a fully closed loop system, we suggest not ruling out the 
intraperitoneal insulin delivery device-subcutaneous glucose sensor combination as 
a viable option. 
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Our objective was to evaluate the accuracy and safety of a real-time (RT) 
continuous glucose monitoring system (CGMS) in patients before and after 
cardiothoracic surgery and to investigate whether activation of the alarm function 
of the RT-CGMS had an effect on glucose control. 
Methods 
Patients scheduled for elective cardiothoracic procedures, without a history of 
insulin-requiring diabetes, were perioperatively monitored with RT-CGMS for 72 h 
and were randomized into two groups: with or without the alarm function (set at 4 
and 10 mmol/L) of the device activated. Sensor values were compared with 
capillary, arterial, and venous blood glucose values. Percentages of time spent in 
various glucose ranges were compared between groups. 
Results 
There were no adverse effects of the RT-CGMS. Of the 1,001 sensor value 
comparisons with capillary or arterial measurements, 96.6% fell within Clarke Error 
Grid zones A and B, with relative absolute differences ranging from 15% 
(preoperative period) to 12% (intensive care unit period) to 14% (postoperative 
period on the ward). Seventeen (7.9%) arterial and 16 (2.0%) capillary comparisons 
fell within zone D or E. Whether or not the alarm function, as used in this pilot 
study, was activated did not affect time spent in different glucose ranges. 
Conclusion 
Although the RT-CGMS is safe and accurate according to accepted standards, there 
are still small aberrations, which in our opinion preclude unlimited use in its present 
form in a clinical setting. The effect of the alarm function at different glucose levels 
remains to be investigated. 
Real-time CGM before and after cardiothoracic surgery 
Introduction 
Van den Berghe et al. reported that strict glycemic control in patients admitted to 
an intensive care unit (ICU) resulted in reduction of morbidity and mortality by 
42.5%.[1] Based on the results of this landmark trial, protocols in ICUs have become 
stricter regarding blood glucose values, and in order to strive for target values 
between 4.4 and 6.1 mmol/L, frequent glucose monitoring and insulin dose 
adjustments are required, which is time intensive.[2] 
Implementing strict glucose control may be facilitated by a real time continuous 
glucose monitoring system (RT-CGMS), when continuous glucose readings can help 
identify and prevent periods of hypoglycemia or hyperglycemia, without increasing 
workload or burden for patients.[3,4] CGMS was shown to be accurate and reliable 
in critically ill patients admitted to the ICU.[4] That study however, was performed 
using retrospective instead of real time glucose data.[4] 
Recently, a new RT-CGMS system reached FDA approval (Paradigm® REAL-Time, 
Medtronic MiniMed, Northridge, CA). RT-CGMS has proven to be effective in 
reducing hyperglycemic and hypoglycemic episodes in ambulatory patients with 
type 1 diabetes.[5,6] However, there is conflicting evidence from randomized 
controlled trials about the effect on HbAlc.[7,8] Piper et al. reported about the 
performance of RT-CGMS during and after cardiac surgery in pediatric patients and 
found RT-CGMS to perform well in hypothermia, inotrope use and edema when 
compared to 6-hourly arterial laboratory glucose values.[9] 
To our knowledge, this is the first study evaluating the accuracy and safety of RT­
CGMS before and after cardiothoracic surgical procedures in adult patients. A 
second objective was to investigate the effect of the alarm function of a RT-CGMS 
on glucose control. 
Research Design and Methods 
Thirty one patients aged over 18 years, undergoing elective cardiothoracic surgery 
without use of insulin before surgery, were included in this study conducted in the 
lsala Clinics, Zwolle, The Netherlands. Approximately 1 week before the scheduled 
surgical procedure, eligible patients received a letter with information about the 
study and were informed that on the day before that procedure, they would be 
contacted by a researcher for further explanation of the trial after which informed 
consent was asked. After admission to the hospital, a clinical history was taken, 
patients underwent physical examination including measurement of blood 
pressure, weight, height and waist circumference, and the Euroscore was calculated. 
The Euroscore provides an estimate of cardiac surgery mortality risk and is based 
on a range of patient and procedure related characteristics.[10] Higher scores 




In general, after surgery, patients would be admitted to the ICU for 1 or 2 days, 
after which they would be transferred to the (medium care) ward for further 
recovery. To test whether the additional alarm function of the RT-CGMS would 
have an effect on glucose control, patients were randomized to RT-CGMS with the 
alarm setting activated or deactivated (Alarm-group and Blind-group, respectively). 
Randomization was done using sealed non-transparent envelopes. Randomization 
took place after informed consent was obtained. This study was conducted with 
approval of the local ethics committee. 
RT-CGMS 
RT-CGMS consists of a needle-type sensor which is inserted in the subcutaneous 
tissue. The sensor is composed of a microelectrode with glucose oxidase. The 
sensor continuously converts small amounts of glucose from the interstitial fluid 
into an electronic signal, the strength of which is proportional to the amount of 
glucose present. The sensor is connected directly with a small oval (~3 x 4 cm) 
transmitter, which wirelessly sends data to a monitor. The sensor performs an 
interstitial glucose measurement every 10 seconds and stores a mean value every 5 
minutes. The sensor lasts a maximum of 72 hours. Calibration is required at least 
every 12 hours. Alarms can be programmed in such a way that the RT-CGMS alerts 
whenever a sensor value is below or above a preset value. 
For the presented study, calibrations were performed 3 or 4 times per 24 hours (i.e. 
after insertion, before surgery, after arrival ICU, before breakfast (8 a.m.), before 
dinner (4 p.m.), before bedtime (10 p.m.)). Alarms were set at 4.0 and 10.0 mmol/L 
(during the night at the ward at 3.0 and 15.0 mmol/L). 
RT-CGMS use was started the day before the planned surgical procedure. The 
sensor was inserted aseptically in the subcutaneous tissue of the abdomen. Sensors 
were calibrated as recommended by the manufacturer, using a capillary blood 
glucose value measured with a point-of-care system (Accu-Chek Inform® System, 
Roche Diagnostics). 
Point-of-care systems are used in our hospital both on the ward and the ICU to 
facilitate strict glucose control with regular glucose monitoring. In our study, all 
blood glucose measurements were performed with this system. Laboratory analysis 
of glucose as a control and calibration of the point-of-care system was performed 
on a regular base. Capillary, arterial and venous blood glucose measurement with 
the Accu-Chek Inform® has proven to be accurate during ICU-admission.[11,12] 
Capillary blood glucose values were obtained at regular pre-specified times. During 
the ICU period, in addition to capillary measurements, arterial and venous blood 
glucose measurements were performed at the same time as the capillary 
measurements. 
In the Alarm-group, whenever the RT-CGMS would alert, a blood glucose value was 
to be determined (either capillary and/or arterial). Treatment decisions were to be 
Real-time CGM before and after cardiothoracic surgery 
taken based on blood glucose values, according to the ICU Insulin/Glucose 
protocol (see supplementary appendix); no treatment adjustments were based on 
sensor values. A continuous intravenous insulin regimen was started pre­
operatively at induction of anesthesia and was continued at the ICU aiming at 
glucose of 4.4-6.1 mmol/L.l At the ward, continuous or intermittent insulin infusion 
was initiated post-operatively at the discretion of the attending physician or the 
consulting internist. 
Whenever a sensor failed during the initiation phase, a new sensor was inserted. 
Whenever a sensor was removed during surgery, a new sensor was placed at arrival 
at the ICU. Total sensor time did not exceed 72 hours in any of the patients. 
Statistical analysis 
Descriptive statistics include mean (standard deviation (SD)) or median 
(interquartile range). All data were reviewed for normality using Q-Q plots and 
parametric and non-parametric test were used as appropriate. Two-tailed tests 
were used and an alpha of 0.05 was used as a threshold of significance. 
To test accuracy, all matched points (within 5 minutes) from both groups were 
plotted on Clarke error grids.[13,14] Clarke error grid analysis was originally 
developed to evaluate the accuracy of capillary blood glucose testing systems 
taking the relevance of differences between reference and measured values into 
account. The reference blood glucose value is plotted on the x-axis against the 
sensor value on the y-axis. The graph is divided into 5 zones. Comparison points 
within zone A represent sensor values that differ from the reference value by no 
more than 20%. Zone B includes comparison points that differ by > 20% but do not 
result in an alteration in treatment. Comparison points in zone C would result in an 
overcorrection of acceptable glucose values. Points in zone D would result in failure 
to detect and treat errors. Comparisons in zone E would result in opposite 
treatment decisions. When over 95% of points are in zone A and B, generally a 
system is considered accurate.[14,15] 
Furthermore, the relative absolute difference (RAD; absolute difference between 
sensor and reference glucose value divided by reference value expressed as a 
percentage) was calculated for capillary values in all periods. This statistic is valued 
as an easy to interpret measure of accuracy.[16] 
To test glucose control, glucose values were divided into 5 ranges (all in mmol/L): 
�3.9; 4.0-4.3; 4.4-6.1; 6.2-10.0; and �10.1. Percentages of time in each range were 
compared between groups in all periods. 
Results 
A total of 31 patients were enrolled from June until October 2007, of which 30 
completed the study (Figure 1). One patient withdrew during the initiation phase of 
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the sensor (first 2 h after sensor insertion) because of increased nervousness due to 
anticipated sensor alarms. 
Figure 1. CONSORT flow chart 
I Assessed for eligibility (n=93) I 
Excluded (n=61 ) 
Not meeting inclusion criteria (n=5) 
Refused to participate (n=46) 
Other reasons (n=1 0) 
I Randomized (n=31 ) I 
I 
Allocated to RT -CGMS with Allocated to RT -CGMS without 
Alarms (n= 1 6) Alarms (n= 1 5) 
Received intervention (n= 1 6) Received intervention (n= 1 5) 
I I 
Lost to follow-up (n=0) Lost to follow-up (n=0) 
Discontinued intervention (n= 1 )  Discontinued intervention (n=0) 
I I 
Analyzed (n= 1 5) Analyzed (n= 1 5) 
Excluded from analysis (n= 1 )  Excluded from analysis (n=0) 
Number of pa rticipants in stages of the trial . Reproduced from CONSORT flow diagram. [17] 
Patient characteristics are presented in Table 1. There were more males and 
patients with type 2 diabetes in the Blind group. 
Median duration of sensor placement was 70.9 (69.9-71.5) h. Sensors were well 
tolerated in all patients, without occurrence of serious adverse skin reactions, 
infections, or bleeding. 
Duration of preoperative sensor placement was 17.5 (15.3-19.2) h; duration of 
postoperative sensor reading was 46.3 (43.8-48.8) h. Median time of sensor reading 
on the ICU was 20.3 (17.6-22.5) h (n = 29; one sensor provided too few sensor 
readings during the ICU stay). Duration of postoperative sensor reading on the 
ward was 28.6 (26.3-29.8) h (n = 26; four patients stayed on the ICU for the 
complete postoperative study period). 
Rea l -time CGM before and after ca rd iothoracic surgery 
Table 1. Patient characteristics 
Characteristic All Alarm-Group Blind-Group 
(n = 30) (n = 15) (n = 15) 
Age (years) 67.8 (9.4) 66.2 (10.3) 69.3 (8.4) 
Male {n) 24 10 14 
BMI (kg/m2) 26.6 (3.4) 26.6 (3.3) 26.6 (3.6) 
Waist (cm) 99.9 (10.7) 98.4 (9.7) 101.4 (11.8) 
Systol ic BP (mm Hg) 121.3 (15.8) 118.2 (17.4) 124.3 (14.1) 
Diastol ic BP (mm Hg) 68.1 (10.9) 64.4 (9.4) 71.9 (11.3) 
Heart rate (bpm) 69.3 (14.6) 71.8 (12.4) 66.9 (16.6) 
Type 2 Diabetes (n) 6 1 5 
Plasma g lucose at admission 5.8 (5.0 - 6.9) 5 .5 (5.0 - 6.6) 5.9 (4.8 - 7.8) 
(non-fasting; mmol/L) 1 
Smoking (n) 5 3 2 
Euroscore 5.7 (3.0) 5.7 (2.8) 5 .8 (3.3) 
Planned procedure (n) 
Coronary artery bypass graft 2 3 
(CABG) 
Va lve procedure (VP) 3 5 
Vascu lar surgery (VS) 2 1 
Rhythm management (RM) 1 
Combined CABG-VP/VS/RM 4 3 
Combined VP/VS/RM 4 2 
Data are means (SD) un less otherwise indicated; 1 = median ( interquarti le range); BMI = Body 
Mass Index; BP = blood pressure 
RT-CG M S: accu racy 
Throughout the study 818 cap i l l a ry b lood g lucose va lues, 216 arteria l  b lood 
g lucose va lues, and 136 venous b lood g lucose va lues were com pared with sensor 
va l ues, resu lting in 39 comparisons per patient on average (range, 24-52). 
Median RAD (absolute d ifference between sensor and cap i l l a ry g l ucose va l ue 
d ivided by cap i l l a ry va lue, expressed as a percentage) d uring the preoperative 
period was 14.6% (range, 7.1-25.9%), during the ICU period was 12.3% (4.7-24.8%), 
and during the postoperative period on the ward was 14.1 % (7.0-25 .4%). 
Cla rke Error Grids of the com parison of sensor and reference va l ues in the 
d ifference periods are shown in Figu re 2. For the comparisons with cap i l la ry 
g lucose measurements, 96.0-99.5% fel l  into g rid zones A and B, the acceptab le 
zones. However, 12 cap i l l a ry points (1.6%) were i n  zone D,  ind icating that the 
sensor va lue wou ld not trigger treatment when the reference va l ue wou ld. Fou r  
points (0.5%) were in  zone E. Zone E represents sensor va l ues that wou ld  trigger 
opposite treatment change than the reference va l ue would .  Comparison of sensor 
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Each g rid shows the comparison of sensor values on the y-axis with g lucose va l ues obtained with 
reference method on the x-axis: A = capi l lary measurements in  pre-operative period; B = capi l lary 
measu rements in ICU period; C = capi l lary measurements in post-operative period on the ward; D 
= arteria l measurements in ICU period; E = venous measurements in ICU period 
Real-time CGM before and after cardiothoracic surgery 
with arterial glucose measurements was less accurate, with 92.1 % (n = 199) of 
comparison points in zones A and B. Comparison of sensor with venous glucose 
measurements was the least accurate, with 21 (15.4%) of comparison points outside 
zones A and B. Points in zones C-E were present in 24 subjects, ranging from one 
to six points per subject. 
RT-CGMS: glucose control 
Preoperative period 
Mean glucose as measured with the sensor in the preoperative period was 6.5 ± 2.0 
mmol/L in the Alarm group and 6.2 ± 0.9 mmol/L in the Blind group (P = 0.51). 
Mean capillary glucose was 6.8 ± 1.0 mmol/L in the Alarm group and 7.2 ± 1.6 
mmol/L in the Blind group (P = 0.47). Figure 3a shows time in glucose ranges for 
both groups in the preoperative period. 
Time spent in euglycemia (4.0-10.0 mmol/L) was 97.2% (88.7-100.0%) in the Alarm 
group and 97.2% (82.8-100.0%) in the Blind group (P = 0.71). Exclusion of patients 
known with diabetes before admission did not change outcome (data not shown). 
During this period, only six alarms (two "High") occurred, in three subjects. On 
average, the same number of capillary measurements was performed in the 
preoperative period (Alarm group, 8.5 ± 1.2; Blind group, 9.3 ± 2.4; P = 0.31). 
Postoperative period 
Mean sensor glucose on the ICU was 6.5 ± 0.8 mmol/L in the Alarm group and 7.7 
± 1.5 mmol/L in the Blind group (P = 0.015). When patients with pre-admission 
diabetes were excluded, this difference was not statistically significant (Alarm 
group, 6.5 ± 0.9 mmol/L; Blind group, 7.4 ±1.5 mmol/L; P = 0.08). Mean capillary 
glucose was 6.7 ± 0.8 mmol/L in the Alarm group and 7.5 ± 1.7 mmol/L in the Blind 
group (P = 0.11; all subjects included). Neither arterial nor venous measurements 
differed between groups (either with or without pre-admission diabetes patients 
included). Median time in target glucose range (4.4-6.1 mmol/L) was 34.8% (17.1-
63.2%) and 20.2% (3.2-38.0%) in the Alarm group and in the Blind group, 
respectively (P = 0.27). Overall, percentage of time spent in the different glucose 
ranges did not differ significantly (Figure 3b). 
Mean sensor glucose on the ward was 8.6 ± 1.7 mmol/L in the Alarm group and 9.5 
± 1.7 mmol/L in the Blind group (P = 0.21). Time in euglycemia was 81.6% (55.4-
96.9%) and 61.2% (30.7-86.3%) in the Alarm group and Blind group, respectively (P 
= 0.15). Overall, the percentage of time spent in the different glucose ranges did 
not differ significantly (Figure 3c). Exclusion of pre-admission diabetes patients did 
not change outcome (data not shown). 
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In the postoperative phase, 104 alarms occurred (90 "High"). Interestingly, the 
number of reference measurements performed per hour was not statistically 
different between groups. During the ICU period, a median of 0.42 (0.37-0.48) 
capillary and 0.30 (0.27-0.42) arterial measurements per hour were performed in 
the Alarm group and 0.42 (0.36-0.44) capillary and 0.31 (0.26-0.43) arterial 
measurements in the Blind group (P = 0.88 and P = 1.00, respectively). 
Real-time CGM before and after cardiothoracic surgery 
During the postoperative period of the study on the ward a median of 0.48 (0.44-
0.56) capillary measurements per hour were performed per patient in the Alarm 
group, as compared to 0.41 (0.39-0.74) in the Blind group (P = 0.41). 
Conclusions 
RT-CGMS proved to be safe regarding local complications or adverse events and is 
accurate when compared with capillary reference values, based on accepted 
measures of accuracy. However, when arterial or venous glucose measurements are 
used as reference, accuracy is only borderline acceptable or not acceptable, 
respectively. The alarm function of the RT-CG MS, as used in this pilot study, had no 
additional effect on glycemic control. 
Our results are in line with previous reported accuracy rate of CGMS; Garg et al.[6] 
reported 96% in Clarke Error Grid zones A and B, and Guerci et al.[18] reported 
even 98.8% in the acceptable zones. Our median RAD ranged from 12.3% to 14.6%. 
Piper et al.[9] reported a mean RAD of 17.6% in their report about the use of RT­
CGMS in pediatric critical ill patients after surgery using arterial glucose values for 
calibration, and others also found comparable RADs.[4,18] To date, there is no 
uniform upper limit of acceptable deviation for these devices, and interpretation of 
reported accuracy differs. Some apply the American Diabetes Association 
requirements for home blood glucose meters (all measurements within 5% of the 
reference value)[19] and conclude that accuracy is too low.[18] Others regard 15% 
as acceptable accuracy.[6] 
In our opinion, sensor readings in the ICU setting need to be more accurate than 
the Clarke Error Grid currently requires, because the intended glucose target range 
is narrower than in ambulatory patients. Moreover, from a safety point of view, the 
occurrence of sensor readings in zones C, D, and E are not acceptable, and one can 
even argue (as De Block et al. [20] did) that points in zone B, indicating more than 
20% deviation from the reference value, are also not acceptable for ICU standards. 
Overall, median time in target glucose range on the ICU was 22.8%, which is in 
accordance with previous published data regarding glucose control on the 
ICU.[20,21] 
The lack of difference in the number of capillary measurements between groups 
could be due to the relatively high number of scheduled measurements by 
protocol, but could also be one of the reasons for not finding an effect of the alarm 
function on glucose control, i.e., alarms did not elicit the required actions and 
reactions. 
There are some limitations to our study. We used capillary measurements to 
calibrate the RT-CGMS throughout the study. This could have influenced the 
reported accuracy of the sensor compared to arterial and venous references 
measurements on the ICU. As can be deduced from Figure 2d, points in zone D of 
1 1sl_ 
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the Clarke Error Grid are close to the border with zone B, and one can speculate 
that when calibration would have been done using arterial glucose values, at least 
some of these points would fall in zone A or B, adding to the accuracy. 
Regarding the effect on outcome, we would like to emphasize that our study was 
not powered to detect a prespecified difference, but was only explorative. 
Furthermore, it is possible that the applied alarm setting was too wide. However, 
setting alarms at a narrower target might have resulted in too many unnecessary 
alarms whereby nurses' workload and the burden for patients would become 
unacceptable high. Furthermore, it was possible, because of the alarms not being 
very loud, that alarms were missed when patients moved around freely on the ward 
or were masked by other alarms and sounds on the ICU. This could have led to a 
delay in action. Second, although a strict glucose protocol was used at our ICU, we 
noticed that blood glucose levels slightly above the target range were accepted by 
the ICU staff and that nurses and physicians were not eager to initiate insulin 
therapy on the ward in the postoperative period in patients without pre-admission 
diabetes. On the ward, higher blood glucose values were accepted, which meant 
that, even when a "High" sensor value was confirmed by the reference glucose, no 
action was taken (or at least not immediately). Our pilot study was not intended to 
interfere with the current glucose protocols and insulin treatment regimens on the 
ICU and the ward, and therefore therapy adjustments on the ward were taken after 
the nurse consulted with the attending physician. This may also have affected the 
outcome of the study, since no proper action was taken to initiate ore alter insulin 
dosage after every sensor alarm all the time. 
We did not measure any severely hypoglycemic glucose values. This might suggest 
that the fear of hazardous hypoglycemia during efforts directed towards strict 
metabolic control is not supported by clinical reality. In a similar patient population, 
Schmeltz et al.[22] reported 1.2% of glucose values < 3.3 mmol/L without any 
episode being considered severe. Because of the limited number of blood glucose 
values in that range, we cannot provide a definite conclusion about the 
performance of the sensor in the hypoglycemic range. 
We conclude that RT-CGMS can be used safely in the peri-operative setting. 
However, with the attitude within our clinic towards peri-operative glucose control, 
use of RT-CGMS with alarm function, as used in this study, does not have a 
different effect than standard glucose monitoring on the ICU or on the medium 
care ward in the post-operative period. Therefore, introducing RT-CGMS does not 
add towards a further improvement of proper glucose control, at least not, when 
only used as a registry device, without promptly and aggressively adapting the 
insulin regime. Combining RT-CGMS with automated adjustments of insulin and/or 
glucose administration might change this conclusion. Nevertheless, in our opinion 
even the small amount of discrepant measurements outside the ranges set, will 
impede, if not prevent, the introduction of such a computed-guided combination. 
Real-time CGM before and after cardiothoracic surgery 
Furthermore, the method of calibrating such devices is of utmost importance and 
we would want to highlight its effect on accuracy and propose a head-to-head 
comparison of a capillary calibrated RT-CGMS with an arterial calibrated RT-CGMS. 
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Supplementary material. ICU Insulin/Glucose Protocol 
Adopted and translated from: Bosman P, van de Wetering K. "Glucoseprotocol IC/CCU" /sala 
Clinics. Zwolle, the Netherlands. First published: 21 -02-2005. Last updated: 08-08-2006 
Objective 
To achieve and maintain a normal blood glucose value (4.4 - 6.1 mmol/L) within 24 
hours during critical illness in patients admitted to the Intensive Care Unit (ICU) or 
Cardiac Care Unit (CCU). 
Patients 
Every patient admitted to the ICU/CCU with an expected stay of more than 2 days 
and every patient admitted after cardiac surgery, with a blood glucose value 
outside the target range of 4.4 - 6.1 mmol/L. 
Methods 
1-hourly measurements of blood glucose are to be performed from admission to 
the ICU / CCU until normal blood glucose value has been achieved. After 
achievement of stable (= 2 consecutive measurements) normal blood glucose, 4-
hourly measurement of blood glucose is sufficient. 
In case of hypoglycaemia or steep increase or decrease of blood glucose values, 
frequent measurement (1-hourly) blood glucose value should be performed. 
Concise Methods 
Target range: 4.4 - 6.1 mmol/L 
1. Determine Initial I.V. insulin bolus and insulin rate 
Blood Glucose 
(mmol/L) 
6.1 - 12.1 
> 12.2 
IV Insulin Bolus 
(units) 
[Blood glucose value] - 4 
[Blood glucose value] - 4 




Real-time CGM before and after ca rd iothoracic su rgery 
2. Action based on next blood g lucose va lue  
Blood Glucose 
(mmol/L} 
Change in IV Insulin rate (units/hour} 
> 12.2 
8.3 - 12.1 
7.0 - 8.3 
6.5 - 7.0 
6.2 - 6.5 
4.4 - 6.1 
4 IU/h increase 
2 IU/h increase 
1 IU/h i ncrease 
0.5 IU/h increase 
0.2 IU/h increase 
3.  Dose adjustment after in it ia l  stab i l isation:  
Blood Glucose Change in IV Insulin 
(mmol/L} rate (units/hour} 
G lu  > 3.9 and 25% !!  
< 2.2 
2 .2 - 3.2 
3.3 - 3.9 
4.0 - 4.3 









50 m l  
Next blood 
glucose value 
1 hou r 
1 hour 
1 hour  
1 hou r 
1 hou r 
I.V. insu l in infusion is stopped upon d ischarge from the ICU/CCU if b lood g lucose is 
maintained in  the target range with an insu l in  i nfusion rate � 2 IU/hour. Before 
d ischarge the blood g lucose va lue has to be < 11.1 mmol/L. 
If more insu l in is necessary to mainta in blood g lucose < 11.1 mmol/L, it is l i kely that 
the patient has pre-exist ing diabetes mel l itus. Consu ltation with the i nternist has to be 
schedu led for adequate fol low up at the ward. 
Reference 
1. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, 
Vlasselaers D, Ferd inande P, Lauwers P, Bou i l lon R. Intensive insu l in therapy in critica l ly 
i l l  patients. N Engl  J Med 2001;345:59-1367 




Summary and future perspectives 
For management of type 1 diabetes mellitus (TlDM) to be completely successful, 
there has to be an effective mode of insulin administration with predictable effects 
combined with a reliable mode of glucose measurement. In this thesis different 
aspects of continuous intraperitoneal insulin infusion (CIPII) as an option for 
intensive insulin therapy in TlDM were investigated. Furthermore, the effectiveness 
and accuracy of (real time) continuous glucose monitoring (CGM) in both patients 
with TlDM using CIPII and a population undergoing cardiac surgery where studied. 
CIPII 
The administration of insulin into the peritoneal cavity rather than in subcutaneous 
tissue may explain the beneficial effect on diabetes control and the lower risk of 
hypoglycaemia when using this treatment modality. Insulin delivered through the 
intraperitoneal (IP) route is almost instantly absorbed and allows blood glucose 
concentrations to return to baseline levels more rapidly and with more predictable 
insulin profiles compared to subcutaneous administration of regular or long-acting 
insulin.[1,2] Furthermore, 99% of the IP insulin is absorbed by the portal system, 
mimicking the physiological situation, probably resulting in higher hepatic insulin 
uptake, which translates into lower peripheral plasma insulin concentrations 
compared with systemic administration.[3] Other consequences might be a more 
adequate glucagon response and improved hepatic glucose production in 
response to hypoglycaemia.[4] 
Although several systems for IP insulin delivery have been tested in the past, only 
one model is available and used for CIPII today, and used in a limited number of 
countries only, mainly in France and The Netherlands. 
In The Netherlands, the Isala Clinics in Zwolle is the centre with the most 
experience. In Chapter 2, glycaemic control, health status and treatment 
satisfaction of subjects treated with CIPII in the Isala Clinics were assessed using a 
retrospective longitudinal analysis of clinical data of the 48 patients who started 
with CIPII between 1983 and 2005. We used HbAlc at baseline, after one year, at 
the end of pump use or the last HbAlc measured before analysis in case of still 
using CIPII at the time of analysis. Furthermore, a cross-sectional assessment of 
health status, well-being and treatment satisfaction was carried out. Almost 70% of 
patients (n = 33) were still treated with CIPII at the moment of assessment. Five 
patients died whilst on CIPII; four from diabetes-related causes, none from 
hypoglycaemia. Mean HbAlc had decreased significantly from 9.7 to 8.8% after one 
year, and to 8.6% after a mean follow up of 6 years. At the same time, less 
hypoglycaemic events were reported at the time of analysis compared to baseline. 
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Treatment satisfaction was high. Mental health status and well-being scores were 
low, however. No formal comparison was made with a control group. 
In Chapter 3 the surgical experience and complications with CIPII were assessed by 
means of a retrospective longitudinal observational cohort study. All patients that 
started with CIPII between 1990 and 2006 in the Isala Clinics in the Netherlands 
were included. The time without the need for an operation, the operation free 
period, and complication rate were compared between patients initiating CIPII 
before 2000 and from 2000 onwards. In 63 patients, 166 re-operations were 
performed during 381 patient-years. Re-operations were necessary for either pump 
replacement due to end-of-battery life (47%), laparoscopic catheter-related 
procedures (29%), or other reasons (24%). Median operation free period increased 
significantly from 21 to 78 months from 2000 onwards. Nineteen percent of 
patients (n = 12) developed complications including infections, pain at the pump 
site, haematoma or cutaneous erosion (9 complications before 2000 versus 10 
complications after 2000). No operation-related mortality was reported. We 
conclude that increased experience together with technical improvements have led 
to an increase of the operation free period. The absence of procedure-related 
mortality and a low complication rate make CIPII a feasible option for patients with 
diabetes. 
In Chapter 4 the results of a prospective cross-over randomized trial regarding the 
effects and safety of CIPII compared with subcutaneous (SC) insulin treatment for 
patients with TlDM in poor glycaemic control are described. The incidence of 
hypoglycaemic events ( < 4.0 mmol/L) was 4.0 (2.6) per week with SC insulin 
compared with 3.5 (2.3) per week during CIPII (p = 0.13). The absolute mean 
difference in HbAlc with CIPII as compared with SC treatment was -0.76% (95% 
confidence interval (CI):-1.41,-0.11). Baseline time spent in euglycaemia was 45.2 
(12.6) % and increased to 52.9 (19.6) % with CIPII (change compared to SC 
treatment: + 10.9% (95% CI:4.6,17.3)). There were no differences in the occurrence 
rate of severe hypoglycaemic events, daily insulin use, or BMI. From these results 
we conclude that, though the reduction in hypoglycaemic events was not 
significant, an improvement of glycaemic control can be achieved with the use of 
CIPII in this group of patients with TlDM with HbAlc levels above 7.5% or frequent 
hypoglycaemic events. 
In Chapter 5 the results regarding quality of life (H RQOL) and treatment 
satisfaction of CIPII compared with SC insulin are presented. Scores were 
significantly higher on the all except two of the SF-36 subscales, and also on the 
component summaries with CIPII compared to SC therapy. Final WHO-5 score with 
IP treatment was 64.9 (22.7) compared to 45.2 (22.7) with SC treatment (p = 
0.0004). Mean difference in treatment satisfaction score at the end of treatment 
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was +9.3 (4.8, 13.9) on a scale of O to 36, favouring CIPII (p = 0.0004). Direct pump­
and procedures associated costs for CIPII were estimated at € 30,901 in the first 
year and € 7,579 per year for the following 6 years, averaging € 10,910 per year, 
compared to an average of € 4,810 yearly costs with continuous subcutaneous 
insulin infusion (CSII). Apart from improving glycaemic control, as described in 
chapter 4, CIPII also leads to improved HRQOL and treatment satisfaction. 
Continuous Glucose Monitoring 
According to international treatment standards and protocols, all patients on 
insulin treatment, regardless of the mode of administration, are instructed to 
perform self-measurement of blood glucose (SMBG) to evaluate the effects of 
insulin treatment, and to obtain reliable information about how to adjust their 
insulin regimen.[S] SMBG is also advised when hypoglycaemia or hyperglycaemia is 
suspected. Still, intermittently performed blood glucose measurements can give 
only limited information regarding the actual 24 hour blood glucose profiles and 
requires the patient to perform a potential painful procedure every time. 
Modes to measure glucose using continuous monitoring have been developed in 
recent decades to help to overcome both disadvantages. 
Currently, most of the available systems measure interstitial fluid glucose levels 
with a glucose oxidase technique, and several manufactures have introduced 
glucose sensors providing direct glucose readings on the market ("Real-time 
Continuous Glucose Monitoring" = RT-CGM).[6] 
Glucose control in the hospital population has gotten much attention after the 
publication of the landmark trial of van den Berg he et al. which concluded that 
strict glycaemic control in patients admitted to an intensive care unit (ICU) resulted 
in a reduction of morbidity and mortality.[13] As a result, protocols in ICUs have 
become stricter regarding blood glucose values.[14] A recent meta analysis showed 
no beneficial effect and a recent trial even showed opposite results, mainly due to 
the increased rate of hypoglycaemia.[15,16] Implementing strict glucose control 
and/or preventing hypoglycaemia may be facilitated by RT-CGM.[14] Instant 
availability to glucose values, together with the option of setting alarms, makes 
continuous subcutaneous glucose sensors even more appealing to patients, 
especially to those who experience frequent or unexpected hypo- and 
hyperglycaemic events; this results in a high user acceptance rate.[7] 
RT-CGM provides 288 glucose values per 24 hour and can therefore help to identify 
abnormal trends in glycaemic profiles which could be overlooked with SMBG, for 
instance hypoglycaemia during night time.[8,9] In theory this would facilitate efforts 




RT-CGM has proven to be effective in reducing hyperglycaemic and hypoglycaemic 
excursions in ambulatory patients with type 1 diabetes mellitus.[10-12] Most of 
these patients were treated with either multiple daily injections (MDI) or CSU, with 
some receiving conventional insulin therapy (1 or 2 injections per day). 
In Chapter 6 an open-label, crossover, randomized study is described, in which we 
tested the effectiveness and safety of RT-CGM in patients treated with CIPII. After a 
baseline period of 3 days, RT-CGM was used for 6 days. As a control, the same 
subjects used CGM without access to the glucose values. Median (range) time 
spent in euglycaemia was 68.2% (55.9 - 72.3%) with RT-CGM and 64.9% (55.3 -
71.2%) with blinded CGM (p = 0.25). Time spent in the hypo- and hyperglycaemic 
ranges did not differ either (p > 0.05). There were no serious adverse events. 
Patient satisfaction was good. Median relative absolute difference between SMBG 
and RT-CGM values was 13.9%. Therefore, we conclude that short-term use of RT­
CGM, although safe and with good patient satisfaction, does not result in more 
time spent in euglycaemia, or less time in hypoglycaemia in our population of 
patients with TlDM receiving CIPII. 
Finally, in Chapter 7, the accuracy and safety of RT-CGM was investigated in 
patients without a history of insulin-requiring diabetes before and after 
cardiothoracic surgery. Fu rthermore, we tested whether activation of the alarm 
function of the RT-CGM had any effect on glucose control. Therefore, we 
monitored patients with RT-CGM for 72 hours and randomized them into 2 groups: 
with or without the alarm function of the device activated. There were no adverse 
effects of the RT-CGM. We used different measures of accu racy, including the 
median relative absolute difference (RAD) and Clarke error grids. The former is the 
absolute difference between sensor and reference glucose value divided by 
reference value, expressed as a percentage and the latter is a scatter of sensor and 
reference values with a grid drawn over it providing different zones of accu racy and 
clinical consequences. We found the sensor to be accurate, based on these 
measures. Therefore our first reaction was to conclude that RT-CGM is safe and 
accurate, and thus might be a valuable addition to the control arsenal. On second 
thought, however, we do deem the cu rrent standards to be not strict enough for 
unrestricted ICU use. The small deviations between glucose levels measu red by RT­
CGM and actual blood glucose levels warrant caution against the unlimited use in 
its present form in a clinical setting. As a practical example, a glucose value of 6.1 
mmol/L with RT-CGM versus 6.5 mmol/L as the actual level will not result in a 
different action in the average ambulatory patient with TlDM. In an ICU-setting, 
however, such only slightly different levels could actually trigger different responses 
in insulin management in severely ill patients. The difference in the example given 
above is that with a glucose value of 6.5 m mol/L the insulin dose will be increased 
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with 0.5 IU per hour, instead of leaving it at the current rate when the glucose is 6.1 
mmol/L. 
Whether or not the alarm function was activated did not affect time spent in 
different glucose ranges. It is possible that results could be different when using 
different settings for the alarms or a more intensive support from the health care 
providers. The effect of the alarm function at different glucose levels remains to be 
investigated. 
Future Perspectives 
Regarding use of RT-CGM, based on this thesis we argue that in its current form it 
is not accurate enough to completely rely on in a clinical setting. We saw no effect 
on glycaemic control in ambulatory patients. However, there is a high treatment 
satisfaction and we hope that in the near future modified and improved versions of 
the device can subject of investigation. 
Based on our results of improved glycaemic control, better HRQOL and high 
treatment satisfaction, we advocate that CIPII remains available as a treatment 
option for patients with TlDM who do not reach good glycaemic control or 
frequently experience unexpected hypoglycaemic events with other intensive 
insulin regimens. This availability will partly depend on continued commitment of 
the present single supplier to the production and further development of 
intraperitoneal pumps. The addition of new manufacturers to this market would 
help. Also, and very important, both regulatory and medical authorities need to 
acknowledge this treatment as a valid treatment modality for a selected group of 
individuals with TlDM. Furthermore, insurance companies will have to start 
reimbursing this expensive form of treatment for this selected patient category. 
Proper guidelines regarding the use of CIPII will be needed, and the Dutch Internist 
Association has proposed selection criteria in a discussion paper in 2007 (see table, 
unpublished data). 
Table. Tentative selection criteria for CIPII therapy 
Subcutaneous insu l in  resistance 
Brittle diabetes 
Insu l in  absorption problems 
Al lergies for need les and plasters, thus hampering or  prec luding the use of MDI and CSII 
Severe l ipohypertrophy and l ipoatrophy 
Insufficient subcutaneous fat tissue 
Need le phobia 
Severe skin scarring and chronic dermatological problems 129 
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In this thesis we tested the efficacy of CIPII in patients with TlDM, with either a 
HbAlc above 7.5%, or more than 5 hypoglycaemic events per week or both. These 
numbers apply to many patients with TlDM. Mean HbAlc at the end of the 
Epidemiology of Diabetes Interventions and Complications (EDIC) study in 2004 for 
instance was 7.9%. That study followed patients with TlDM for a total of 17 
years.[17] One can therefore even argue that CIPII should be considered in a larger 
part of the TlDM population than only in patients meeting above stated criteria. 
Furthermore, because of the clear benefits of CIPII regarding H RQOL, one of the 
questions to answer in the future is whether we can consider CIPII as a valid option 
for those patients who are already in good glycaemic control, but experience a low 
quality of life due to the negative aspects of other intensive insulin regimens. Such 
an approach would be quite revolutionary, though, and the hypothesis regarding 
improvement of H RQOL with CIPII as a valid and consistently reproducible 
treatment goal will need to be investigated. 
In order to obtain a glucose regulation within the limits of normal for prolonged 
periods in people with TlDM, there are only a few viable options, amongst them 
pancreas transplantation and beta cell transplantation.[18] The sheer amount of 
subjects with TlDM versus the potential availability of donor pancreata precludes 
the use of pancreas transplantation as the solution for large groups of patients. 
Also, beta cell transplantation will only be available to few selected patients, as long 
as the source of beta cells is human donors. Furthermore, immunosuppressive 
treatment will still be necessary with both types of transplantation, with all its side 
effects. Last but not least, most of these transplantations do not result in a 
complete return to normoglycaemia for a life time.[18,19] 
Research with living donor islet transplantation or xenogeneic islets obtained from 
porcine pancreata or stem cell research might lead in the future to an inexhaustible 
supply of active beta cells, thus allowing even multiple implantations in an 
individual. Still, many problems have to be solved, before such a solution will be 
safe, straightforward to use, and available on a large scale.[19] 
In the mean time, a viable alternative would still be a further development of a 
mechanical solution, including the already available pump for CIPII. The ultimate 
goal in such an effort would be to link continuous glucose measurements to insulin 
administration without the need for the patient to have to act as a mediator. i.e. to 
create a closed loop system. Although we have shown that CIPII can be used as a 
reliable mode for insulin administration, the presently available CGM systems are 
not yet reliable enough to be used in such a closed loop system. Furthermore, most 
systems still need a subcutaneously placed sensor, while ideally, a combination of 
an internal pump with an intravascular placed sensor would allow the best possible 
combination, with the least lag time.[20] Some data regarding different 
---- -----, 
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approaches, like the combination of an IP pump with IV glucose sensing, are 
coming forward, but results are still not as convincing as hoped for.[20] 
Future research will have to focus on aspects like a more reliable and smaller CIPII 
device with a prolonged battery life, implantable glucose sensors with a negligible 
lag time, and reliable algorithms to allow a proper balance between glucose levels 
and insulin delivery. 
Up to now, we have been able to show positive effects from CIPII on glucose 
metabolism, with more time in euglycaemia. Other positive effects of IP 
administered insulin are also both hypothesized and described. When assessing the 
effects of intraperitoneal insulin delivery there is also some evidence that IP insulin 
may have a positive effect on lipid status.[22] And in a dog model, IP insulin 
resulted in higher energy expenditure, which may eventually lead to less weight 
gain than with systemic insulin administration. Furthermore, protein synthesis was 
altered during IP versus systemic insulin administration, and resembled more 
closely the non-diabetic situation. These phenomena are hypothesized to result 
from higher hepatic uptake of insulin and lower peripheral insulin levels.[23] 
Whatever the effects are on the occurrence of complications is yet to be 
determined. In the near future we will be able to investigate the protein synthesis 
of our subjects on CIPII, in order to confirm or refute these results found in diabetic 
dogs. 
In the coming years, we will also assess the long term effects of CIPII in our patient 
population. As stated in Chapter 4, all patients at the end of the prospective trial 
chose to continue with CIPII. It will be interesting to perform a long term follow up 
of these patients, regarding glycaemic control, complications and HRQOL in order 
to assess whether the results of our 6 month study are reproducible over a longer 
period of time. 
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Samenvatting en toekomstperspectieven (Dutch summary) 
Een succesvolle behandeling van type 1 diabetes mellitus (TlDM) moet bestaan uit 
een effectieve manier van insuline toediening met voorspelbare effecten in 
combinatie met een betrouwbare manier van het meten van glucosewaarden. 
In dit proefschrift zijn verschillende aspecten van continue intraperitoneale insuline 
infusie (CIPII) als een manier van intensieve insuline therapie in TlDM onderzocht. 
Daarnaast is de effectiviteit en betrouwbaarheid van een ('real time') continue 
glucose monitor (CGM) in zowel patienten met TlDM die CIPII gebruiken als een 
groep patienten die hartchirurgie kregen onderzocht. 
CIPII 
Het gunstige effect op de glucoseregulatie en het verminderde risico op 
hypoglycemie dat gezien wordt bij CIPII ontstaat waarschijnlijk door insuline toe te 
dienen via de peritoneaalholte in plaats van het subcutane weefsel. Intraperitoneale 
insuline wordt bijna direct geabsorbeerd waarna de glucoseconcentratie in het 
bloed sneller en meer voorspelbaar daalt dan met subcutane toediening van 
gewone of langwerkende insuline.[1,2] Daarnaast wordt 99% van de 
intraperitoneale insuline door het portale adersysteem geabsorbeerd, net zoals dat 
in de fysiologische situatie gebeurd. Dit leidt waarschijnlijk tot een hogere 
insulineopname in de lever en zodoende tot een lagere perifere 
insulineconcentratie in vergelijking met systemische toediening van insuline.[3] Oak 
een betere glucagonrespons en hogere glucoseproductie door de lever als reactie 
op een hypoglycemie dragen bij.[4] 
In de loop van de jaren zijn meerdere systemen voor intraperitoneale 
insulinetoediening ontwikkeld en getest. Op dit moment is er echter maar 1 model 
beschikbaar voor CIPII, welke in een beperkt aantal landen wordt gebruikt, met 
name in Frankrijk en Nederland. 
De Isala Klinieken te Zwolle zijn het centrum met de meeste ervaring met CIPII in 
Nederland. In Hoofdstuk 2 warden de glycemische controle, gezondheidstoestand 
en patienttevredenheid beschreven van mensen die behandeld warden met CIPII in 
de Isala Klinieken. De gegevens van 48 patienten die met CIPII startten tussen 1983 
en 2005 zijn gebruikt voor een retrospectieve longitudinale analyse. We vergeleken 
het HbAlc bij starten, na 1 jaar en aan het eind van CIPII of wel het laatst bekende 
HbAlc als een patient ten tijde van de analyse nag steeds aan CIPII deed. 
Daarnaast deden we een crossectionele analyse van de gezondheidstoestand, het 
welbevinden en de patienttevredenheid. Bijna 70% van de patienten (n = 33) werd 
op het moment van analyse nag behandeld met CIPII. Vijf patienten zijn overleden 
terwijl zij CIPII gebruikten; vier aan een diabetesgerelateerde oorzaak, geen als 
gevolg van een hypoglycemie. Het gemiddelde HbAlc daalde significant van 9,7 
naar 8,8% na 1 jaar, en naar 8,6% na een gemiddelde follow-up van 6 jaar. 1 37 
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Tegelijkertijd werden er minder hypoglycemieen gerapporteerd ten tijde van de 
analyse dan aan de start van CIPII. 
De patienttevredenheid was hoog. Scores voor psychische gezondheidstoestand en 
welbevinden waren echter laag. Er werd niet vergeleken met een controle groep. 
In Hoofdstuk 3 onderzoeken we de chirurgische ervaring en complicaties met CIPII 
door middel van een retrospectieve longitudinale observationele cohortstudie. Alie 
patienten die met CIPII zijn begonnen tussen 1990 en 2006 in de Isala Klinieken 
werden ge·includeerd. De tijd die verstreek zonder dat er een heroperatie nodig 
was, de operatievrije periode, en het aantal complicaties werd vergeleken tussen 
patienten die voor 2000 en patienten die vanaf 2000 met CIPII waren begonnen. 
Gedurende 381 patientjaren werden er bi j 63 patienten 166 heroperaties 
uitgevoerd. In 47% van de gevallen bestond de heroperatie uit het vervangen van 
de pomp vanwege het bereiken van het einde van de batteri jduur. In 29% van de 
gevallen werd er een laparoscopische kathetergerelateerde procedure uitgevoerd 
en voor 24% van de heroperaties was er een andere reden. De mediale 
operatievrije periode nam significant toe van 21 tot 78 maanden vanaf 2000. In 
19% van de patienten (n = 12) deed zich een complicatie voor; onder andere 
infectie, pijn op de plek van de pomp, hematoomvorming of erosie van de huid (9 
complicaties voor 2000 versus 10 complicaties vanaf 2000). Er was geen 
operatiegerelateerde mortaliteit. Concluderend zorgen een toename van de 
operatie-ervaring in combinatie met technische verbeteringen voor een verlenging 
van de operatievrije periode. Vanwege de afwezigheid van proceduregerelateerde 
mortaliteit en een laag complicatiepercentage kan CIPII overwogen warden als 
behandeling bij mensen met diabetes. 
In Hoofdstuk 4 warden de resultaten van een prospectieve cross-over 
gerandomiseerde studie naar de effecten en de veiligheid van CIPII in vergelijking 
met subcutane insuline behandeling bij mensen met TlDM met een slechte 
glycemische controle beschreven. 
De incidentie van hypoglycemieen (glucose < 4.0 mmol/L) was 4,0 (2,6) per week 
met subcutane insuline en 3,5 (2,3) per week met CIPII (p = 0.13). Het absolute 
gemiddelde verschil in HbAlc met CIPII in vergelijking met subcutane behandeling 
was -0,76% (95% betrouwbaarheidsinterval (BI):-1,41; -0,11). Bij het begin van de 
studie werd 45,2 (12,6)% van de tijd in euglycemie doorgebracht. Dit percentage 
steeg naar 52,9 (19,6)% met CIPII. De verandering ten opzichte van subcutane 
insuline was +10,9% (95% BI:4,6; 17,3). Er was geen verschil in aantallen ernstige 
hypoglycemieen, in totale hoeveelheid insuline die gebruikt werd of in BMI. Aan de 
hand van deze resultaten concluderen we dat, alhoewel er een niet significante 
vermindering van het aantal hypoglycemieen is, er wel een verbetering van de 
glycemische controle wordt bereikt met CIPII in deze groep patienten met TlDM 
en een HbAlc boven de 7,5% of frequente hypoglycemieen. 
Samenvatting en toekomstperspectieven (Dutch summary) 
In Hoofdstuk 5 warden de resultaten betreffende de gezondheidsgerelateerde 
kwaliteit van !even (Kvl) en de patienttevredenheid met CIPII in vergelijking met 
subcutane insuline therapie gepresenteerd. De scores op 6 van de 8 SF-36 
subschalen en oak de totaalscores voor zowel psychische en lichamelijke 
gezondheid waren significant hoger voor CIPII dan voor subcutane therapie. De 
WHO-5 totaalscore (schaal 0 - 100) was 64,9 (22,7) in vergelijking met 45,2 (22,7) 
met subcutane therapie (p < 0,01). Deze resultaten duiden op betere Kvl met CIPII 
dan met subcutane therapie. Het gemiddelde verschil in patienttevredenheid aan 
het einde van de behandeling was + 9,3 (4,8; 13,9) op een schaal van 0 tot 36, in 
het voordeel van CIPII (p < 0,01). Directe pomp- en procedure geassocieerde 
kosten werden voor CIPII geschat op € 30.901,- in het eerste jaar en € 7.579,- per 
jaar voor de volgende 6 jaren. Gemiddeld kost CIPII € 10.910,- per jaar in 
vergelijking met een gemiddelde jaarprijs van € 4.810,- voor continue subcutane 
insuline infusie (CSII). Geconcludeerd werd dat CIPII niet alleen de glycemische 
controle zoals in Hoofdstuk 4 wordt beschreven verbetert, maar oak de Kvl en de 
patienttevredenheid. 
Continue Glucose Monitoring 
Alie patienten die insuline gebruiken, ongeacht de manier van toediening, moeten 
volgens de (internationale) richtlijnen zelfcontrole van de bloedglucose (self 
monitoring of blood glucose; SMBG) toepassen. Hiermee kan het effect van de 
insulinebehandeling geevalueerd warden en kan aan de hand van de gemeten 
waarden zo nodig de insulinedosis aangepast worden.[5] SMBG kan oak verricht 
warden bij het vermoeden op een hypo- of hyperglycemie. Toch geven dergelijke 
intermitterende bloedglucosemetingen maar een beperkte hoeveelheid informatie 
over het gehele 24-uurs bloedglucoseprofiel en is er elke keer een potentiele 
pijnlijke vingerprik voor nodig. 
Er zijn manieren ontwikkeld om continu de glucose te meten waardoor 
bovenstaande problemen kunnen warden opgelost. De huidige beschikbare 
systemen maken bijna allemaal gebruik van een glucose oxidase meettechniek die 
de glucoseconcentratie in de interstitiele vloeistof meet. Verschillende fabrikanten 
hebben vervolgens een sensor op de markt gebracht waarbij de gemeten 
glucoseconcentratie direct afgelezen kan warden. We spreken oak wel van een 
"real-time" continue glucose monitor (RT-CGM).[6] 
Glucoseregulatie tijdens ziekenhuisopname staat sinds de publicatie van de studie 
van Van Den Berghe en collega's in de belangstelling. Zij concludeerden dat strikte 
glycemische controle in patienten op de intensive care zorgt voor een daling van 
de morbiditeit en mortaliteit.[13] Als gevolg hiervan zijn de protocollen wat betreft 
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de glucoseregulatie op !Cs aangescherpt.[14] Een meta-analyse liet echter geen 
gunstig effect zien en in een recente studie werd zelfs een tegengesteld resultaat 
gevonden, vooral door het vaker optreden van hypoglycemieen.[15,16] Strikte 
glucosecontrole danwel het voorkomen van hypo's zou door het gebruik van RT­
CGM vergemakkelijkt kunnen worden.[14] Door het direct beschikbaar zijn van de 
glucosewaarden en de mogelijkheid om alarmen in te stellen zijn deze continue 
sensoren aantrekkelijk voor patienten, zeker voor diegenen die regelmatig of 
onverwacht hypo- of hyperglycemische episodes hebben. Er is dan oak een hoge 
gebruikersacceptatie.[7] 
Doordat de sensor 288 glucosewaarden per 24 uur genereert, wordt het mogelijk 
om abnormale trends in het 24-uursglucoseprofiel op te sporen die met SMBG 
misschien ongemerkt zouden blijven, zoals nachtelijke hypoglycemieen.[8,9] In 
theorie zou hiermee een (bijna-) normaal bloedglucoseprofiel bereikt kunnen 
warden. 
Bij mensen met type 1 diabetes die niet opgenomen zijn in het ziekenhuis kan met 
RT-CGM het aantal hypo- en hyperglycemische uitschieters vermindert 
worden.[10-12] Dit is voornamelijk onderzocht bij mensen die multiple dagelijkse 
injecties (MDI) of CSII gebruiken. 
In Hoofdstuk 6 wordt de open-label, cross-over, gerandomiseerde studie 
beschreven waarin we de effectiviteit en veiligheid van de RT-CGM in patienten die 
met CIPII behandeld warden onderzochten. Na een baseline periode van 3 dagen 
werd de RT-CGM 6 dagen gebruikt. Als controle gebruikten dezelfde deelnemers 
oak een CGM zonder dat de glucosewaarden zichtbaar waren. Met de RT-CGM was 
de mediane (range) tijd die in euglycemie werd doorgebracht 68,2% (55,9 - 72,3%) 
in vergelijking met 64,9% (55,3 - 71,2%) gedurende de geblindeerde CGM periode 
(p = 0,25). Oak de ti jd die in hypo- of hyperglycemie werd doorgebracht verschilde 
niet tussen de beide periodes (p > 0,05). Er deden zich geen ernstige bijwerkingen 
voor en de patienttevredenheid was goed. Het mediane relatieve verschil tussen de 
SMBG waarden en de RT-CGM glucosewaarden was 13,9%. 
We hebben daarom geconcludeerd dat kortdurend gebruik van RT-CGM veilig is 
en met een goede patenttevredenheid gepaard gaat, maar dat het niet zorgt voor 
meer tijd in euglycemie, of minder tijd in hypoglycemie in onze groep mensen met 
TlDM die CIPII gebruiken. 
Dan als laatste wordt in Hoofdstuk 7 de veiligheid en nauwkeurigheid van de RT­
CGM onderzocht in een groep patienten zonder insuline afhankelijke diabetes 
random een cardiothoracale operatie. Daarnaast hebben we getest of het instellen 
van de alarmfunctie van de RT-CGM een effect heeft op de glucoseregulatie. De 
patienten werden gerandomiseerd over 2 groepen (wel of geen alarmfunctie) 
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waarna de RT-CGM 72 uur werd gebruikt. Er deden zich geen complicaties van de 
RT-CGM voor. 
Om de nauwkeurigheid te onderzoeken hebben we gebruik gemaakt van 
verschillende methodes, waaronder het mediane relatieve absolute verschil en 
Clarke error grids. Bij de eerste methode wordt het absolute verschil tussen de 
sensorwaarde en de referentiewaarde gedeeld door de referentiewaarde en 
uitgedrukt als een percentage. Een Clarke error grid is een puntenwolk van de 
sensorwaarden uitgezet tegen de referentiewaarden waarover een raster is 
getekend waardoor er verschillende zones ontstaan van nauwkeurigheid en 
klinische consequentie. Als we uitgaan van deze methodes dan blijkt de RT-CGM 
nauwkeurig en dus was de eerste reactie om te concluderen dat de sensor veilig en 
nauwkeurig is en mogelijk een waardevolle aanvulling van het diagnostische 
arsenaal. Echter, wanneer nogmaals gekeken wordt naar de specifieke situatie van 
de intensive care, dan moeten we concluderen dat de huidige 
nauwkeurigheidseisen niet streng genoeg zijn om gebruik op de IC zonder 
restricties te adviseren. Dit vanwege kleine verschillen tussen de waarde die 
gemeten wordt door de RT-CGM en het daadwerkelijke bloedglucosegehalte. 
Verschillen die waarschijnlijk voor een patient in de dagelijkse thuissituatie niet van 
belang zijn, kunnen dat wel zijn tijdens een ziekenhuis- of IC-opname. Om een 
voorbeeld te geven: Een gemeten sensorwaarde van 6,1 mmol/L zal, als er in 
werkelijkheid een bloedglucosewaarde is van 6,5 mmol/L in de thuissituatie niet tot 
een andere reactie leiden. Echter, een zelfde verschil zal in een ernstige zieke 
patient op de IC een andere reactie tot gevolg hebben op basis van het strikte 
glucoseregulatie protocol dat daar gehanteerd wordt; bij een waarde van 6,5 
mmol/L zal de insulinedosering verhoogd warden met 0,5 IE/uur, in plaats van deze 
te laten staan op de huidige stand bij een waarde van 6,1 mmol/L. 
Het wel of niet instellen van de alarmfunctie heeft geen effect op de tijd die in 
respectievelijk hypo-, eu- of hyperglycemie wordt doorgebracht. Andere 
alarminstellingen of intensievere begeleiding van de patienten zouden mogelijk 
andere uitkomsten kunnen geven. Met name het effect van andere 
alarmglucosewaarden moet nag onderzocht warden. 
Toekomstperspectieven 
Gebaseerd op de gegevens uit dit proefschrift stellen wij dat de RT-CGM, in zijn 
huidige vorm niet nauwkeurig genoeg is om in de ziekenhuisomgeving volledig op 
te kunnen vertrouwen. We zagen geen effect op de glycemische controle bij niet 
opgenomen patienten. Toch is er een grate mate van patienttevredenheid en we 
hopen dat er in de nabije toekomst verbeterde versie beschikbaar komen voor 
vervolgonderzoek. 
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Gebaseerd op de resultaten van een verbeterde glycemische controle, betere Kvl 
en grotere patienttevredenheid willen we pleiten voor het beschikbaar blijven van 
CIPII als behandelmogelijkheid voor patienten met TlDM die niet is staat zijn om 
met een andere manier van intensieve insuline therapie een acceptabele 
glycemische controle te bereiken of daarmee veel of onverwachte hypoglycemieen 
hebben. Deze beschikbaarheid zal ten dele afhangen van de betrokkenheid van de 
huidige enige aanbieder bij de productie en voortgaande ontwikkeling van de 
intraperitoneale pomp. Toestroming van nieuwe aanbieders op de markt zou 
hierbij kunnen helpen. Daarnaast moeten zowel de regelgevende als de medische 
instanties deze therapie als een valide behandeloptie aanmerken voor een 
geselecteerde groep patienten met TlDM. Ziektekostenverzekeraars zouden 
daarop deze dure behandelvorm moeten vergoeden. Er moeten richtlijnen komen 
aangaande de indicaties voor CIPII. De Nederlandsche internisten vereeniging heeft 
in 2007 een voorstel gedaan over de indicaties voor CIPII (zie de tabel, 
ongepubliceerde gegevens). 
Tabel. Selectiecriteria voor CIPII 
Subcutane insuline resistentie 
Labiele, of zogenaamde 'Brittle' diabetes 
Vertraagde insuline absorptie 
Allergie voor naalden en pleistermateriaal, waardoor MDI en CSII niet mogelijk zijn 
Lipohypertrofie en lipoatrofie 
Zeer magere mensen 
Naald fobie 
Ernstige littekens en chronische dermatologische problemen 
In dit proefschrift hebben we de effectiviteit van CIPII onderzocht in patienten met 
TlDM met ofwel een HbAlc boven de 7.5%, en/of meer dan 5 hypoglycemieen per 
week. Veel patienten met TlDM voldoen aan deze criteria. Het gemiddelde HbAlc 
aan het einde van de " Epidemiology of Diabetes Interventions and Complications" 
(EDIC) studie in 2004 was bijvoorbeeld 7.9%. In de EDIC studie werden patienten 
met TlDM 17 jaar gevolgd.[17] Op basis van deze gegevens kan beargumenteerd 
warden dat CIPII overwogen dient te warden in een grater deel van de TlDM 
populatie dan alleen de patienten die aan bovenstaande zeer strikte criteria 
voldoen. Daarnaast zorgen de duidelijke voordelen die CIPII op het gebied van Kvl 
laat zie ervoor dat er oak een antwoord gegeven moeten warden op de vraag of 
CIPII niet een valide behandeloptie is voor die patienten die wel een goede 
glycemische regulatie hebben, maar een lage Kvl ervaren door de negatieve 
aspecten van andere intensieve insuline therapieen. Verbetering van Kvl als een 
valide en reproduceerbaar behandeldoel vergt echter nag aanvullend onderzoek 
en is op dit moment nag niet een indicatie voor CIPII. 
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Om voor een langere tijd een normale glucoseregulatie te bewerkstelligen in 
patienten met TlDM zijn er op dit moment een aantal opties, waaronder 
pancreastransplantatie en betaceltransplantatie.[18] Alleen al vanwege het aantal 
patienten met TlDM in vergelijking tot het potentiele aantal donorpancreata lijkt 
de toepassing van pancreastransplantatie niet de oplossing voor een grate groep 
patienten. Ook betaceltransplantatie zal niet op grate schaal toegepast kunnen 
warden zolang de herkomst van de betacellen humane donoren zijn. 
Immunosuppressieve therapie met al de bekende bijwerkingen blijft daarnaast 
noodzakelijk bij beide types van transplantatie. Als laatste kan nog genoemd 
warden dat met de meeste van deze transplantaties er niet een levenslange 
terugkeer naar normoglycemie kan warden bereikt.[18,19] 
Wie weet gaat onderzoek naar transplantatie van levende eilandjes of xenogene 
eilandjes verkregen van varkenspancreata of stamcelonderzoek in de toekomst een 
onuitputtelijke bran van betacellen opleveren waardoor zelfs meerdere 
transplantaties in 1 individu tot de mogelijkheden gaan behoren. Toch moeten er 
nog vele problemen warden opgelost voordat een dergelijke innovatie veilig , 
makkelijk toepasbaar en op grate schaal beschikbaar zal zijn.[19] 
Ondertussen zou een haalbaar alternatief een verdere ontwikkeling van een 
mechanische oplossing kunnen zijn met de huidige pomp voor CIPII als basis. Het 
ultieme doel van een dergelijke ontwikkeling is dan om continue glucose metingen 
te linken aan de afgifte van insuline zonder de tussenkomst van de patient. Zo'n 
systeem wordt ook wel een 'closed loop' genoemd. In dit proefschrift hebben we 
aangetoond dat met CIPII insuline betrouwbaar en effectief kan warden 
toegediend. Echter de huidige beschikbare continue glucose monitor systemen zi jn 
nog niet betrouwbaar genoemd om in een dergelijk closed loop systeem te 
functioneren. De meeste CGMs maken nog steeds gebruik van een subcutane 
sensor. De combinatie van een inwendige pomp met een intravasculaire sensor 
zorgt waarschijnlijk voor de minste vertragingstijd.[20] Er zijn resultaten bekend 
over combinaties zoals die van een intraperitoneale pomp met een intraveneuze 
sensor, maar deze zijn nog niet zo overtuigend als wel werd gehoopt.[20] 
Toekomstig onderzoek zal zich moeten richten op onder andere het nog 
betrouwbaarder en kleiner maken van de CIPII pomp, het verlengen van de 
batterijduur, de ontwikkeling van een implanteerbare glucosesensor met een te 
verwaarlozen vertragingstijd en betrouwbare algoritmen om de juiste afstemming 
tussen glucosewaarden en insulineafgifte te bereiken. 
We zijn in staat gebleken om positieve effecten van CIPII op onder andere het 
glucosemetabolisme te laten zien. Andere positieve effecten van CIPII warden ook 
gehypothetiseerd en beschreven in dit proefschrift. Andere onderzoekers vonden 




een diermodel zorgde IP insuline voor meer energ ieverbruik, iets wat weer kan 
leiden tot minder gewichtstoename, in vergelijking met systemisch toegediende 
insuline. Oak werd een veranderde, meer op de niet-diabetische gelijkende, 
eiwitsynthese gezien tijdens IP insuline toediening in vergelijking met systemische 
insuline toediening. Een hogere insulineopname door de lever en lagere perifere 
insulineconcentraties warden in verband gebracht met deze resultaten.[23] Of er 
oak een effect om het optreden van complicaties is, is niet duideli jk. In de nabije 
toekomst zullen we in staat zi jn de eiwitsynthese ti jdens CIPII te onderzoeken om 
zo de resultaten uit het diermodel te reproduceren dan wel tegen te spreken. 
In de komende jaren zullen we de langetermi jneffecten van CIPII in onze 
patientpopulatie kunnen beoordelen. Zoals in Hoofdstuk 4 al werd beschreven, 
hebben alle deelnemers aan de prospectieve studie er voor gekozen met CIPII door 
te gaan. Een follow up betreffende glycemische controle, complicaties en Kvl zal 
duidelijk maken of de resultaten uit de 6 maanden periode na een langere periode 
reproduceerbaar zijn. 
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